

**NHS South Yorkshire Integrated Medicines Optimisation Committee (IMOC)**






**Traffic Light Drug List**

**May-26**

**\*\*\*This list is in development and is being led by the SY IMOC, currently it does not include medicines where the 4 places (Barnsley, Doncaster and Bassetlaw, Rotherham and Sheffield) have previously agreed at place based TL status. Harmonisation of placed based TLDL is underway with the long-term vision to have one TLDL for South Yorkshire.**

**Due to the extensive number of green drugs, currently not all will be listed within the SY TLDL. During the process of merging the 4 place TLDLs across South Yorkshire, green drugs will be added to the IMOC**

**\*\*\*Formulary status of these drugs will be decided by each Place\*\*\***

	Grey Traffic light Status		Red traffic Light Status		Green Traffic Light Status
	Amber Traffic Light Status		Amber G Traffic Light Status		

[Refer to the user guide for classification rationale: Click here](#)

**Remember : Control + F to search this list**

<b>SY Place based Formularies :</b>	
<a href="#">Barnsley Place Formulary</a>	<a href="#">Rotherham Place Formulary</a>
<a href="#">Doncaster Place Formulary</a>	<a href="#">Sheffield Place Traffic Light Drug List</a>

Traffic Light Status	Drug/Product	Brand name	Rationale / criteria	Notes	Date Considered	Review date	Relevant Links
Grey	Aceclofenac		3	Non-steroidal anti-inflammatory	Jun-23		
Grey	Adagrasib		6	Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)	Aug-25		<a href="#">NICE TA1076</a>
Grey	Adrenaline (nasal spray formulation) (Dual Traffic Light status)	EURneffy®	7	Emergency treatment of severe allergic reactions (anaphylaxis)	Dec-25		
Grey	Afamelanotide		1	Erythropoietic protoporphyria	Sep-23		
Grey	Agomelatine		3	Major Depression	Jun-23		<a href="#">NICE TA821</a>
Grey	Alimemazine (dual traffic light classification)		4	All licensed indications-urticaria and pruritus( already traffic lighted Amber if initiated for sleep disorders in children by tertiary sleep service in SCH (unlicensed indication)	Feb-25		
Grey	Aliskiren		1	Hypertension	Jun-23		<a href="#">Link to NHSE LLP1</a>
Grey	Almotriptan		4	Refer to Place based formularies / guidelines for alternative listing	Jun-24	Jun-25	<a href="#">Link to NHSE LLP1</a>
Grey	Amantadine (Multiple traffic light classification)		2	Influenza	Jun-23		
Grey	Amifampridine (3,4 diaminopyridine phosphate)		1	Lambert-Eaton Myasthenic Syndrome (LEMS) in adults	Jun-23		

Grey	Anakinra (dual traffic light classification)		2	Rheumatoid arthritis in adults	Jun-23		<a href="#">NICE NG100</a> <a href="#">Also see reference to Red traffic light status</a>
Grey	Angiotensin II		2	Treatment of refractory hypotension in adults with septic or other distributive shock	Apr-24		
Grey	Antimalarials (dual traffic light combination)		2	Prophylaxis treatment of malaria	Apr-24		<a href="#">Drugs for malaria prophylaxis are not prescribable on the NHS.</a> <a href="#">Chloroquine &amp; atovaquone 250 mg / proguanil 100mg is available to buy over-the-counter.</a> <a href="#">Mefloquine and doxycycline are only available on private prescription.</a>
Grey	Aprocitentan		6	Resistant hypertension	Apr-25		
Grey	Armour thyroid (desiccated thyroid extract )		1	Hypothyroidism	Jun-23		<a href="#">Link to SPS advice</a>
Grey	Atorvastatin 30mg and 60mg tablets		4	For cost-effective prescribing it is recommended that for patients requiring a 30mg or 60mg dose to use 10mg or 20mg tablets	Jun-24	Jun-25	
Grey	Avanafil		4	Erectile dysfunction	Feb-24		
Grey	Axicabtagene ciloleucel (dual Traffic light status)		2	Refractory follicular lymphoma	Jul-23		<a href="#">NICE TA894</a>
Grey	Azathioprine 75mg & 100mg strengths (dual Traffic Light Status)		3		Apr-24		
Grey	Azilsartan		4	Hypertension	Feb-24		

Grey	Baloxavir marboxil		2	Uncomplicated influenza and post exposure prophylaxis of influenza in patients aged 12 years and above	Jun-23	
Grey	Baloxavir marboxil		7	Treating and preventing influenza in children 1 to 11 years (terminated appraisal)	Mar-26	<a href="#">NICE TA1135</a>
Grey	Bemiparin		6	All licensed indications	Jun-23	
Grey	Calcifediol	Domnisol®	7	Treatment of vitamin D deficiency in adults, prevention of vitamin D deficiency in adults with identified risks, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency	Dec-23	
Grey	Cangrelor tetrasodium		7	Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy	Jan-26	<a href="#">NICE TA1102</a>
Grey	Casirivimab plus imdevimab		1	Covid-19 Treatment	Jun-23	<a href="#">NICE TA878</a>
Grey	Cedazuridine + decitabine		2	Acute myeloid leukaemia	Mar-24	
Grey	Cemiplimab		2	with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer	Dec-25	<a href="#">NICE TA1108</a>
Grey	Cerliponase alfa		7	Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2	Mar-26	<a href="#">HST34</a>

<b>Grey</b>	Chikungunya vaccine		6	Active immunisation for the prevention of disease caused by chikungunya virus	Aug-25	
<b>Grey</b>	Chondroitin (all salts, all strengths)		1,2	All Indications	Jul-23	<a href="#">In NHSE guidance</a>
<b>Grey</b>	Ciclesonide	Alvesco®	4	Refer to Place based formularies / guidelines for alternative listing	Sep-23	
<b>Grey</b>	Cilostazol		2	Intermittent claudication in patients without rest pain and no peripheral tissue necrosis	Jul-23	<a href="#">NICE TA223</a>
<b>Grey</b>	Ciltacabtagene autoleucel		6	Treatment of adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide	Mar-25	
<b>Grey</b>	Ciprofibrate		4	Refer to Place based formularies / guidelines for alternative listing	Jul-24	
<b>Grey</b>	Clascoterone		6	Topical treatment of acne vulgaris in patients aged ≥12 years	May-25	
<b>Grey</b>	Clascoterone		6	For treating acne vulgaris in people 12 years and over (terminated appraisal)	Nov-25	<a href="#">NICE TA1105</a>
<b>Grey</b>	Clobetasol propionate/neomycin sulphate/nystatin 0.5mg/5mg/100,000 IU/g Cream/ointment		4	Refer to Place based formularies / guidelines for alternative listing	Jul-23	

Grey	Cobimetinib		2	Unresectable or metastatic melanoma in adults	Jul-23		<a href="#">NICE TA414</a>
Grey	Co-diovan		4	Hypertension	Sep-23		For cost-effective prescribing it is recommended that valsartan plus bendroflumethiazide should be prescribed separately
Grey	Concizumab		6	Treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)	May-26		<a href="#">NICE TA1124</a>
Grey	Co-Proxamol		1	All licensed indications	Jun-23		<a href="#">NHSE Guidance</a>
Grey	Cyanocobalamin 50 microgram tablets (dual traffic light combination)		1	Dietary Supplement	May-23		<a href="#">NHSE items that should not routinely prescribed</a> <a href="#">Also see reference to Green traffic light status</a>
Grey	Darifenacin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey	Darvadstrocel		2	Fistulas (perianal) in adult patients with non-active/mildly active luminal Crohn's disease.	Sep-23		
Grey	Decitabine (Including combinations)		7	Myeloid Leukaemia	Nov-24		<a href="#">Decitabine NICE Information</a>
Grey	Deflazacort		4	Steroid	Feb-24	Feb-25	
Grey	Dekas plus liquid (dual traffic light classification)			Non- Cystic fibrosis patients Also see Green for children under 3 with cystic fibrosis	Oct-23		
Grey	Dengue vaccine	Qdenga®	1	Prevention of dengue disease in individuals aged ≥4 years	Oct-23		

Grey	Depemokimab		7	Treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)	Feb-26	<a href="#">NICE TA1123</a>
Grey	Dexketoprofen		5	Nonsteroidal anti-inflammatory drug (NSAID)	Feb-24	
Grey	Dicycloverine Hydrochloride tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23	<a href="#">Medicines Optimisation Information</a>
Grey	Diphtheria + tetanus + pertussis vaccine		6	Active immunisation against tetanus, diphtheria and pertussis in persons aged $\geq 4$ years as a booster following primary immunisation. Also for passive protection against pertussis in early infancy following maternal immunisation during pregnancy	May-24	
Grey	Donanemab		6	Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adults that are apolipoprotein E $\epsilon 4$ heterozygotes or non-carriers	Jan-25	
Grey	Dosulepin		1	Depressive illness, particularly where sedation is required	Jun-23	<a href="#">Link to NHSE LLP1</a>
Grey	Doxazosin MR preparations		1	Hypertension	Jun-23	<a href="#">Link to NHSE LLP1</a>
Grey	Doxepin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23	
Grey	Doxepin cream		3	Pruritus in eczema	Jul-23	

Grey	Dupilumab (Dual traffic light status)		8	Maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils. Grey classification will be reviewed when a plan to support implementation has been agreed.	May-26		<a href="#">NICE TA1142</a>
Grey	Dutasteride 500mcg plus tamsulosin 400microgram		4	For cost-effective prescribing it is recommended that Dutasteride and Tamsulosin are prescribed separately	Sep-23		
Grey	Efgartigimod for treating antibody-positive generalised myasthenia gravis		2	Efgartigimod for treating antibody-positive generalised myasthenia gravis	Jul-25		<a href="#">NICE TA 1069</a>
Grey	Elacestrant		6	Use as monotherapy for the treatment of postmenopausal women and men with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor	Nov-24		
Grey	Elotuzumab		7	For previously treated multiple myeloma	May-25		<a href="#">Elotuzumab NICE information</a>
Grey	Entrectinib		7	for treating NTRK fusion-positive solid tumours in people 12 years and over.	Feb-26		<a href="#">NICE TA1118</a>

Grey	Epcoritamab		5	Monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy	Feb-24		
Grey	Erdosteine		3	Symptomatic treatment of acute exacerbations of chronic bronchitis	Jul-25		
Grey	Eroxon Stimgel		7	Treatment of erectile dysfunction in adult men [medical device – gel formulation of volatile solvent components]	Jun-23		
Grey	Esketamine		2	Major depressive disorder in adults at imminent risk of suicide	Jul-23		<a href="#">NICE TA899</a>
Grey	Esketamine Nasal spray		2	Depression	Sep-23		
Grey	Eszopiclone		7	Insomnia	Apr-25		
Grey	Eyelid hygiene preparations		3	Examples : wipes,lotions	Sep-23		
Grey	Fampridine		2	Multiple sclerosis	Sep-23		<a href="#">NICE NG220</a>
Grey	Fentanyl (Immediate release)		1	For patients not undergoing palliative care treatment as per NHSE guidelines	Dec-23		<a href="#">NHS E Guideline</a>
Grey	Fluoxetine 10mg tablets (refer to the green entry for other strengths/formulations)		4	Cross reference to green traffic light entry for other strengths/formulations	Mar-26		The capsule formulation has a significantly lower acquisition cost
Grey	Flurbiprofen tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey	Fluvastatin 80mg		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		

Grey	Fosdenopterin		7	Treating molybdenum cofactor deficiency type A (terminated appraisal)	Aug-25	<a href="#">NICE TA1078</a>
Grey	Gamolenic acid (Evening Primrose Oil)		3		Sep-23	
Grey	Ganaxolone		2	Treating seizures caused by CDKL5 deficiency disorder in people 2 years and over	Mar-25	
Grey	Gefapixant		7	Refractory or unexplained chronic cough	Jun-24	
Grey	Givinostat		6	Treatment of Duchenne muscular dystrophy in patients aged 6 years and older	Apr-26	<a href="#">NICE TA in development</a>
Grey	Glasdegib		1	Terminated NICE TA	Sep-23	<a href="#">NICE TA646</a>
Grey	Glucosamine and chondroitin		1		Sep-23	<a href="#">NHSE guidance</a>
Grey	Gluten Free products			Coeliac Disease, gluten sensitive enteropathies, dermatitis herpetiformis or other gluten intolerances in line with SYICB position statement	Jan-26	<a href="#">SY Gluten Free information</a>
Grey	Gonadotrophin releasing hormone (GnRH) analogues drugs- medicines that consist of, or contain, buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin.		2	Used to suppress puberty as part of treating gender incongruence or gender dysphoria in children and young people who are under 18 years of age	Jun-24	<a href="#">NHSE Information</a>
Grey	Herbal treatments		1	Not Recommended	Oct-23	<a href="#">NHSE document</a>
Grey	Homeopathic treatments		1	Not Recommended	Oct-23	<a href="#">NHSE document</a>
Grey	Human alpha1-proteinase inhibitor		7	Treating emphysema	May-24	

Grey	Hyaluronic acid Intra-articular injections		2	Do not offer intra-articular hyaluronan injections to manage osteoarthritis	Oct-23		<a href="#">NICE NG226</a>
Grey	Idecabtagene vicleucel		6	Treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)	Aug-25		<a href="#">NICE TA 1084</a>
Grey	Inavolisib		6	Use in combination with palbociclib and fulvestrant for the treatment of adults with PIK3CA-mutated, oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.	Apr-26		<a href="#">NICE TA in development</a>
Grey	Inositol nicotinate		2	Intermittent claudication in people with peripheral arterial disease	Oct-23		
Grey	Insulin needles >£5 per 100 needles		4		Sep-23		<a href="#">Refer to Place based formularies/ guidelines supported by NHSE document</a>
Grey	Iptacopan		1,6	Treating complement 3 glomerulopathy	Dec-25		<a href="#">NICE TA1107</a>
Grey	IQoro		3	Neuromuscular training device	Feb-23		

Grey	Ketoprofen (topical)		3	Areas of skin treated with Ketoprofen 2.5 % Gel should not be exposed to direct sunlight, or solarium ultraviolet light, either during treatment or for two weeks following treatment discontinuation, in order to avoid phototoxicity reactions and photoallergy	Oct-23		
Grey	Lazertinib		6	Advanced non-small cell lung cancer	Jun-25		<a href="#">On publication of NICE TA</a>
Grey	Lecanemab		6	Alzheimer's disease	Feb-25		
Grey	Leniolisib phosphate		6	Indicated for the treatment of activated phosphoinositide 3-kinase delta (P13Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Mar-25		
Grey	Levodopa inhalation powder	Inbrija®	7	Intermittent treatment of episodic motor fluctuations (OFF episodes) in adults with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor	Nov-25		
Grey	Loxapine		2	Mild-to-moderate agitation in patients with schizophrenia or bipolar disorder	Oct-23		
Grey	Lutein and antioxidants (All dietary antioxidants and supplements to prevent AMD)		1	Age related macular degeneration (AMD)	Oct-23		<a href="#">NHSE document</a>

<b>Grey</b>	Melphalan flufenamide		7	Relapsed or refractory multiple myeloma	Jun-24		
<b>Grey</b>	Memantine orodispersible tablets		4	Memantine tablets are 1st line. If oral solution is required for cost-effective prescribing it is recommended that oral solution is prescribed where clinically appropriate. See Place guidance for further prescribing information.	Nov-23	Nov-24	
<b>Grey</b>	Methocarbamol		1	Short-term symptomatic relief of muscle spasm	Nov-23		
<b>Grey</b>	Methylnaltrexone bromide injection		2	Execption prescribe on advice of the specialist Palliative Care team	Nov-23		
<b>Grey</b>	Minocycline		1	Acne Vulgaris and Acne Rosacea	Nov-23		<a href="#">NHSE guidelines</a>
<b>Grey</b>	Mosunetuzumab		2	Follicular lymphoma	Nov-23		<a href="#">NICE Information</a>
<b>Grey</b>	Naltrexone/bupropion prolonged-release tablets		2	Weight Management	Jul-23		<a href="#">NICE TA494</a>
<b>Grey</b>	Necitumumab		2	Lung cancer	Nov-23		<a href="#">Necitumumab NICE information</a>
<b>Grey</b>	Netarsudil + latanoprost 50micrograms/200 micrograms in 1mL eye drops		6	Primary open-angle glaucoma or ocular hypertension	Sep-23		
<b>Grey</b>	Nintedanib		6	Treating fibrosing interstitial lung disease in people 6 to 17 years	Dec-25		<a href="#">Nintedanib NICE Informormation</a>

Grey	Niraparib + abiraterone		6	Use with prednisone or prednisolone for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated	Apr-26		<a href="#">NICE TA in development</a>
Grey	Olipudase alfa		7	Treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B	May-25		<a href="#">NICE hst32</a>
Grey	Olmesartan and amlodipine		4	For cost-effective prescribing it is recommended that olmesartan and amlodipine prescribed separately	Nov-23		
Grey	Omaveloxolone		7	Treating Friedreich’s ataxia in people 16 years and over	Dec-25		<a href="#">NICE TA1061</a>
Grey	Omega-3 fatty acids (Eicosapentaenoic acid /Docosahexaenoic acid )		1	For the primary and secondary prevention of cardiovascular events	Sep-23		<a href="#">NHSE guidance</a>
Grey	Osilodrostat		1,7	Endogenous Cushing's syndrome	Nov-23		
Grey	Oxerutins		3	Oedema associated with chronic venous insufficiency	Nov-23		
Grey	Padeliporfin		2	For untreated, unilateral, low-risk prostate cancer in adults	Dec-23		
Grey	Palopegteriparatide		6	Indicated for the treatment of adults with chronic hypoparathyroidism-	Oct-24		<a href="#">NICE TA in development</a>
Grey	Paracetamol and tramadol combination		1	Analgesic	Dec-23		<a href="#">NHS E Guideline</a>

Grey	Pegaptanib		2	Neovascular age related macular degeneration	Dec-23		
Grey	Pegylated liposomal irinotecan		7	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer	May-25		<a href="#">NICE TA1052</a>
Grey	Pentoxifylline		2	Intermittent claudication in people with peripheral arterial disease	Jul-23		<a href="#">NICE TA223</a>
Grey	Perindopril arginine		1	Angiotensin converting enzyme (ACE) inhibitors	Dec-23		<a href="#">NHS E Guideline</a>
Grey	Phenylephrine OTC preparations (oral/nasal) (dual classification)		1	For OTC preparations. See also see red list	Oct-25		
Grey	Pioglitazone and Metformin combination tablets		4	For cost-effective prescribing it is recommended that Pioglitazone and Metformin are prescribed separately	Dec-23	Dec-24	
Grey	Piroxicam (oral)		3	Nonsteroidal anti-inflammatory drug (NSAID)	Dec-23		
Grey	Pirtobrutinib	Jaypirca®	6	Use as monotherapy for the treatment of adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor, and use as monotherapy for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia who have been previously treated with a BTK inhibitor	Dec-25		

Grey	Pitolisant (dual classification)		2	Excessive daytime sleepiness caused by obstructive sleep apnea. See also Red for other indications	Dec-25		
Grey	Ranitidine		3	H2-receptor antagonists	Dec-23	Dec-24	
Grey	Recombinant Parathyroid hormone		1,6	All licensed indications	Oct-25		<a href="#">Parathyroid hormone NICE information</a>
Grey	Rehydration solutions/sachets (dual traffic light status)		1	Self care-acute Diarrhoea (adults)	Feb-24		<a href="#">SY Selfcare Guide</a>
Grey	Resperate® Device		1		Dec-23		
Grey	Riboflavin		2,3	Migraine	Feb-24		<a href="#">NICE CG150 – can be purchased OTC</a>
Grey	Ripretinib		2	Gastrointestinal stromal tumour	May-23		<a href="#">NICE TA881</a>
Grey	Rizatriptan lyophilisate	Maxalt®	4	Migraine	Feb-24	Feb-25	
Grey	Rosuvastatin Capsules		4	For cost effective option prescribe tablets, exception being opening capsules for swallowing difficulties & mixed with soft food for oral administration or administered via nasogastric tube.	Jul-24	Jul-25	
Grey	Rozanolixizumab		1,6	Indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-musclespecific tyrosine kinase (MuSK) antibody positive.	Aug-24		
Grey	Rubefacients		1	Self-care - as per NHSE Guidelines	Dec-23		<a href="#">NHS E Guideline</a>

Grey	Rupatadine		4	Refer to Place based formularies / guidelines for alternative	Dec-23	Dec-24	
Grey	Satralizumab		7	Preventing relapses in neuromyelitis optica spectrum disorders	May-24		<a href="#">Sarilumab NICE Information</a>
Grey	Satralizumab		2	Use as a monotherapy or in combination with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorders in adults and adolescents aged $\geq 12$ years who are anti-aquaporin-4 IgG seropositive	Apr-24		
Grey	Sebelipase alfa (dual traffic light combination)		7	Lysosomal acid lipase (LAL) deficiency - long term enzyme replacement therapy (ERT) cross reference to Red TLS	Feb-24		
Grey	Seladelpar	Livdelzi®	6	Treatment of primary biliary cholangitis, including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA	Dec-25		
Grey	<a href="#">Self-care medicines - All Conditions for which over the counter items should not routinely be prescribed in primary care</a>		5	Various Over the Counter medicines That are considered to be self-limiting i.e short term symptoms	Jun-23		
Grey	Selinexor		6	Multiple myeloma	Mar-24		

Grey	Serplulimab	Hetronify®	6	Use in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer	Dec-25		
Grey	Sildenafil brand: Viagra® (For Erectile Dysfunction) (multiple traffic light classifications)	Viagra®	4	Erectile Dysfunction. See also sildenafil entry in green and red sections. Follow Place formularies / guidelines for further information	Apr-25		
Grey	Silk Garments		1	In line with NHSE guidance Items not to be routinely prescribed in primary care	Dec-23		<a href="#">NHS E Guideline</a>
Grey	Simple eye ointment		4	Refer to Place based formularies / guidelines for alternative	Dec-23		
Grey	Sirolimus		6	for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Jun-24		
Grey	Sirolimus gel		6	Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged ≥6 years	Dec-23		
Grey	Sodium Phenylbutyrate (Dual Classification)		6	For treating amyotrophic lateral sclerosis, see red traffic light list for other indications	Nov-25		<a href="#">Sodium Phenylbutyrate NICE information</a>
Grey	Sotatercept		6	Pulmonary arterial hypertension	Aug-25		
Grey	Sulindac		3,4	Gout	Dec-23	Dec-24	
Grey	Sulthiame		6	Rolandic epilepsy	Apr-25		

<b>Grey</b>	Sumatriptan + naproxen sodium combination		4,7	Acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient	Jul-25		
<b>Grey</b>	Sumatriptan dispersible tablets	Imigran® Radis	4	Migraine	Feb-24	Feb-25	
<b>Grey</b>	Sun protection		Self care -1	Self care - Exception as per Advisory Committee on Borderline Substances (ACBS) approved indications.	Dec-23		
<b>Grey</b>	Tabelecleucel		2	Treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus	Nov-23		<a href="#">NICE TA923</a>
<b>Grey</b>	Tadalafil 2.5mg only		4		Jul-24		
<b>Grey</b>	Tadalafil brand: Cialis® (For Erectile Dysfunction) (multiple traffic light classifications)	Cialis®	4	Erectile Dysfunction . See also tadalafil entries in green section and red sections. Follow Place formularies / guidelines for further information	Apr-25		
<b>Grey</b>	Tafamidis (dual traffic light combination)		2	Wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults Also see reference to Red traffic light status	Dec-23		
<b>Grey</b>	Tamsulosin plus solifenacin combination tablets		4	For cost-effective prescribing it is recommended that Tamsulosin and Solifenacin are prescribed separately	Dec-23	Dec-24	

Grey	Tamsulosin MR tablets		4	For cost-effective prescribing it is recommended that Tamsulosin MR capsules are prescribed	Dec-23	Dec-24	
Grey	Tarlatamab		6	Small cell lung cancer	Apr-25		
Grey	Telmisartan & Hydrochlorothiazide	Micardis Plus®	4	Refer to Place based formularies / guidelines for alternative listing	Nov-23		
Grey	Temsirolimus		2	All licensed indications	Feb-24		<a href="#">Temsirolimus NICE Information</a>
Grey	Teplizumab		6	To delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes	Feb-26		TA expected April 2026
Grey	Teprotumumab	Tepezza®	6	Use in adults for the treatment of moderate to severe thyroid eye disease	Dec-25		
Grey	Tiaprofenic acid		3	Pain and inflammation in rheumatic disease and other musculoskeletal disorders	Feb-24		<a href="#">Important safety information For tiaprofenic acid CSM advice</a>
Grey	Tirzepatide weight management - any use outside of NICE TA1026 criteria [Multiple traffic light classifications]			Any patients that fall outside of NICE TA1026 criteria.	Nov-25		<a href="#">NICE TA1026</a>
Grey	Tislelizumab		7	Terminated appraisals	Jul-25		<a href="#">NICE TA 1068 &amp; TA 1072-terminated appraisals</a>
Grey	Tixagevimab plus cilgavimab		2	Preventing COVID-19	Jul-23		<a href="#">NICE TA900</a>

Grey	Tofersen	Qalsody®	6	Treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene	Dec-25		
Grey	Trastuzumab deruxtecan		6	Treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments	Dec-25		
Grey	Travel Vaccines		1	Except for: cholera, diphtheria/tetanus/polio, hepatitis A, typhoid	Oct-23		<a href="#">NHSE Guidance</a>
Grey	Trimipramine		1	Antidepressant	Jul-23		<a href="#">NHS E Guidance</a>
Grey	Vinflunine		2	Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	Feb-24		
Grey	Vitamin supplements and tonics		1	In line with SY Selfcare Guide	Feb-24		<a href="#">SY Selfcare Guide</a>
Grey	Zilucoplan		6	Use as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive	May-24		
Grey	Zuranolone	Zurzuvae®	6	Treatment of moderate or severe postnatal depression in adults following childbirth	Dec-25		
Red	Rezafungin		1,6	Treatment of adults with invasive candidiasis	May-24		
Red	Abacavir(including combinations)		1,6	HIV infection	Feb-24		
Red	Abaloparatide		1,6	Treating osteoporosis after menopause	Oct-24		

Red	Abatacept		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Abatacept NICE information</a>
Red	Abciximab		1,6	Monoclonal antibody	Feb-24		
Red	Abemaciclib		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Abemaciclib NICE Information</a>
Red	Abiraterone		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Abiraterone NICE Information</a>
Red	Abrocitinib		1,6	Atopic dermatitis	Feb-24		
Red	Acalabrutinib		1,6	Chronic lymphocytic leukaemia	Feb-24		
Red	Acetylcysteine ampoules		1	Emergency Treatment of Poisoning (paracetamol)	Feb-24		
Red	Aciclovir IV		1,6		Apr-24		
Red	Acitretin		1	Psoriasis	Feb-24		
Red	Acoramidis		1,6	Treating transthyretin amyloidosis with cardiomyopathy	Feb-26		<a href="#">NICE TA 1121</a>
Red	Activated Charcoal		1,6	Emergency Treatment of Poisoning ('many oral poisons')	Apr-24		
Red	Activated Protein C	Ceprotrin®	1,6	Congenital protein C deficiency	Apr-24		
Red	Adalimumab		1,2,6	In line with positive NICE TA recommendations	Jun-23		<a href="#">Adalimumab NICE information</a>
Red	Adefovir		1	Chronic hepatitis B	Feb-24		
Red	Adenosine	Adenocor®	1,6	Supraventricular arrhythmias	Apr-24		
Red	Afatinib		1,6	Non-small cell lung cancer	Feb-24		
Red	Aflibercept		1,2	In line with positive NICE TA recommendations	Jun-23		<a href="#">Aflibercept NICE information</a>
Red	Agalsidase alfa & beta		1,6	Fabry's disease	Apr-24		
Red	Albendazole		1,6		Apr-24		
Red	Albutrepenonacog alfa		1	Treatment and prophylaxis of bleeding in patients with haemophilia	Feb-24		

<b>Red</b>	Aldesleukin		1,6	In line with positive NICE TA recommendations	Apr-24	
<b>Red</b>	Alectinib		1,6	for adjuvant treatment of ALK-positive non-small-cell lung cancer	Dec-24	<a href="#">Alectinib NICE Information</a>
<b>Red</b>	Alemtuzumab		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Alemtuzumab NICE information</a>
<b>Red</b>	Alirocumab		1,6	Primary hypercholesterolaemia	Feb-24	
<b>Red</b>	Alitretinoin		1	Eczema - refractory chronic hand (severe)	Feb-24	
<b>Red</b>	All human coagulation factor IX		1	All licensed indications	Oct-25	
<b>Red</b>	All Intravenous nutrition		1,6		Apr-24	
<b>Red</b>	Alpelisib	Piqray®	1,6	Indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy	Apr-24	
<b>Red</b>	Alteplase		1,6		Apr-24	
<b>Red</b>	Ambrisentan		1	Pulmonary arterial hypertension	Feb-24	
<b>Red</b>	Amikacin		1,6	In line with positive NICE TA recommendations	Apr-24	

<b>Red</b>	Aminolevulinic acid products		1,5	Actinic keratosis on face, scalp (mild to moderate) and other body regions Field cancerisation. Basal cell carcinoma (superficial and/or nodular )	Feb-24	
<b>Red</b>	Aminophylline IV		1,6		Apr-24	
<b>Red</b>	Amivantamab (including in combination)		1,6	In line with positive NICE TA recommendations	Apr-24	<a href="#">Amivantamab NICE Information</a>
<b>Red</b>	Amphotericin		1,6	Antifungal	Apr-24	
<b>Red</b>	Anagrelide		1,6	Polycythaemia vera, Thrombocytosis,	Apr-24	
<b>Red</b>	Anakinra (dual traffic light classification)		1,6	Still's disease & Gout Also see reference to Grey traffic light status	Feb-24	
<b>Red</b>	Andexanet alpha		1,6	In line with positive NICE TA recommendations	Feb-25	<a href="#">Andexanet+alfa NICE Information</a>
<b>Red</b>	Anhydrous sodium thiosulfate		1,6	In line with positive NICE TA recommendations	Feb-25	<a href="#">Anhydrous+sodium+thiosulfate NICE Information</a>
<b>Red</b>	Anidulafungin		1,6	Invasive candidiasis	Apr-24	
<b>Red</b>	Anti-D (Rh0) Immunoglobulin		1,6		Apr-24	
<b>Red</b>	Antihemophilic factor/Von Willebrand factor complex		1,6	Congenital Von Willebrand Disease	Apr-24	
<b>Red</b>	Anti-lymphocyte immunoglobulin (horse) (Atgam®)		1,6	Treatment of acquired moderate to severe aplastic anaemia	Apr-24	
<b>Red</b>	Antimalarials (dual traffic light classification )		1,6	For treatment of malaria	Apr-24	

Red	Antithrombin		1,6	VTE - Prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency	May-24	
Red	Anti-thymocyte immunoglobulin (Rabbit)		1,6	Immunosuppression in solid organ transplantation	Oct-25	
Red	Apalutamide		1,6	Prostate Cancer (non-metastatic castration-resistant)Metastatic Hormone Sensitive Prostate Cancer	May-24	
Red	Apraclonidine		1,6	Glaucoma (short-term adjunctive therapy of chronic glaucoma)	May-24	
Red	Apremilast		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Apremilast NICE information</a>
Red	Aprepitant		1,6	Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.	May-24	
Red	Arachis hypogaea		1,6	Peanut Allergy	May-24	
Red	Argatroban		1,6	Anticoagulation of patients with heparin-induced thrombocytopenia type II requiring parenteral antithrombotic therapy	May-24	
Red	Argipressin		1,6	Indicated in adults for the treatment of diabetes insipidus, when this is not of nephrogenic origin, and for control of bleeding from oesophageal varices.	May-24	

Red	Arsenic trioxide		1,6	Acute promyelocytic leukaemia (relapsed/refractory)	May-24	
Red	Artesunate		1	Initial treatment of severe malaria in adults and children	Dec-24	
Red	Asciminib		1,6	Chronic myeloid leukaemia	May-24	
Red	Ascorbic Acid Injection/Infusion		1,6	Treatment of clinical vitamin C deficiency not amenable to dietary supply or oral replacement therapy in adults	May-24	
Red	Asenapine		1,6	Manic episodes (moderate to severe) associated with bipolar I disorder	May-24	
Red	Asfotase alfa		1,6	Hypophosphatasia - long term enzyme replacement therapy (ERT)	May-24	
Red	Asparaginase		1,6	Acute lymphoblastic leukaemia	May-24	
Red	Ataluren		1,6	Duchenne muscular dystrophy	May-24	
Red	Atazanavir (including combinations)		1,6	HIV Infection in combination with other antiretroviral drugs	May-24	
Red	Atezolizumab		6	In line with positive NICE TA recommendations	Apr-25	<a href="#">Atezolizumab NICE Information</a>
Red	Atidarsagene autotemcel		1,6	Metachromatic leukodystrophy	May-24	
Red	Atovaquone		1,6		May-24	
Red	Autologous cell/blood related		1,6	In line with positive NICE TAs	Oct-24	<a href="#">Autologous NICE information</a>
Red	Avacopan		1,6	NHSE commissioned.	May-24	
Red	Avalglucosidase alfa		1,6	Pompe disease	Apr-23	Apr-27 <a href="#">NICE TA821</a>
Red	Avapritinib		1,6	Treating advanced systemic mastocytosis	Dec-24	<a href="#">Avapritinib NICE Information</a>

Red	Avatrombopag		1,6	In line with positive NICE TA recommendations	May-24		<a href="#">Avatrombopag NICE Information</a>
Red	Avelumab (including in combination)		1,6	As per licenced appropriate NICE TA	Jun-23		<a href="#">Avelumab NICE information</a>
Red	Avibactam(including in combination with other drugs)		1	Antibiotic	Aug-24		
Red	Axicabtagene ciloleucel		1,6	Refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Jul-23		<a href="#">NICE TA895</a>
Red	Axitinib		1,6	In line with positive NICE TAs	Oct-24		<a href="#">Axitinib NICE information</a>
Red	Azacitidine		1,6	Myeloid leukaemia (Acute), Myelodysplastic syndromes. Chronic or Acute myelomonocytic leukaemia	May-24		
Red	Aztreonam		1,6				
Red	Aztreonam + avibactam		1	Antibiotic	Nov-24		
Red	Bacillus Calmette-Guerin	OncoTICE®	1,6	Bladder instillation			
Red	Baricitinib		1,6	In line with positive NICE TA recommendations	Dec-23		<a href="#">Baricitinib NICE information</a>
Red	Baricitinib (dual classification)		1,3	Adults and children COVID-19 Treatment	Jun-23	Oct-25	<a href="#">NICE NG191</a>
Red	Basiliximab		1,6	Renal transplantation (immunosuppressive therapy)	Jun-24		
Red	Bedaquiline		1,6	Tuberculosis	Jun-24		
Red	Bee Venom (Alutard Bee Venom®)		1,6	Allergy Immunotherapy	Jun-24		
Red	Belantamab mafodotin		1,6	Multiple myeloma	Jun-24		<a href="#">Belantamab mafodotin NICE Information</a>
Red	Belatacept		1,6	Prophylaxis of graft rejection in adult recipients of a renal transplant	Jun-24		
Red	Belimumab		1,6	In line with positive NICE TA recommendations	Jun-24		<a href="#">Belimumab NICE information</a>

Red	Belumosudil		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Belumosudil NICE information</a>
Red	Belzutifan		6	In line with positive NICE TA recommendations	Jun-23		<a href="#">Belzutifan NICE Information</a>
Red	Bendamustine		1,6	Chronic lymphocytic leukaemia, multiple myeloma	Jun-24		
Red	Benperidol		1	Antipsychotic	Feb-24		
Red	Benralizumab		1,6	In line with positive NICE TA recommendations	Jun-24		<a href="#">Benralizumab NICE Information</a>
Red	Benzyloxyphenylpenicillin benzathine		1,6		Jun-24		
Red	Beractant		1,6	Pulmonary surfactants	Jun-24		
Red	Berotrastat		1,6	NHSE commissioned.	Jun-24		
Red	Beta Interferon		1,6		Jun-24		
Red	Betaine		1,6	Drugs used in metabolic disorders	Jun-24		
Red	Betamethasone injection		1,6	Status asthmaticus, shock from surgery/trauma, acute adrenal crisis, soft tissue lesions	Jun-24		
Red	Betula verrucosa		1	Treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen	Sep-25		<a href="#">NICE TA1087</a>
Red	Bevacizumab		1,6	In line with positive NICE TA recommendations	Jun-23		<a href="#">Bevacizumab NICE information</a>
Red	Bexarotene		1,6	Cutaneous T-cell lymphoma (CTCL) - skin manifestations of advanced stage	Jun-24		
Red	Bezlotoxumab		1,6	Prevention of recurrence of Clostridium difficile infection (CDI)	Jun-24		
Red	Bictegravir/emtricitabine/tenofovir alafenamide		1,6	Adults infected with human immunodeficiency virus-1 (HIV-1)	Jun-24		

Red	Bimekizumab		1	In line with positive NICE TA recommendations	Nov-23		<a href="#">Bimekizumab NICE information</a>
Red	Binimetinib		1,6	In line with positive NICE TA recommendations			<a href="#">Binimetnib NICE information</a>
Red	Birch bark extract	Filsuvez®	1,6	Treating epidermolysis bullosa	Oct-23		
Red	Bivalirudin		1,6				
Red	Bleomycin		1,6				
Red	Blinatumomab		1,6	In line with positive NICE TA recommendations	May-25		<a href="#">Blinatumomab NICE Information</a>
Red	Bortezomib		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Bortezomib NICE information</a>
Red	Bosentan		1	Pulmonary arterial hypertension & Systemic sclerosis with ongoing digital ulcer disease	Oct-23		
Red	Bosutinib		1,6	Chronic myeloid leukaemia	Jun-24		
Red	Botulinum toxin type A		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Botulinum toxin type A NICE information</a>
Red	Brentuximab vedotin		1,6	in line with positive NICE TA Recommendations	Jun-25		<a href="#">Brentuximab+vedotin NICE Information</a>
Red	Brexucabtagene autoleucel		1,6	Refractory B-cell acute lymphoblastic leukaemia	Jul-23		<a href="#">NICE TA893</a>
Red	Brigatinib		1,6	Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Jun-24		
Red	Brodalumab		1,6	Psoriasis (moderate to severe plaque ) in adult patients who are candidates for systemic therapy.	Jun-24		
Red	Brolucizumab		1,6	Neovascular (wet) age-related macular degeneration (AMD)	Jun-24		

Red	Bromfenac		1,6	Ocular inflammation following cataract extraction in adults.	Jun-24	
Red	Budesonide 4mg m/r capsule	Kinpeygo®	1,6	Targeted-release budesonide for treating primary IgA nephropathy	Mar-26	<a href="#">NICE TA1128</a>
Red	Budesonide orodispersible tablet	Jorveza®	1,6	In line with positive NICE TA recommendations	Jun-24	<a href="#">Budesonide Orodispersible tablet NICE information</a>
Red	Bulevirtide		1,6	Treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adults with compensated liver disease	Jul-23	<a href="#">NICE TA896</a>
Red	Bupivacaine		1,6	Local and surgical anaesthesia	Jun-24	
Red	Buprenorphine		1	Opioid dependence	Feb-26	
Red	Buprenorphine/Naloxone		1	Opioid drug dependence	Nov-25	<a href="#">Buprenorphine/naloxone NICE information</a>
Red	Burosumab		1,6	In line with positive NICE TA recommendations	Oct-24	<a href="#">Burosumab NICE Information</a>
Red	Buserelin		1,6	Infertility	Jul-24	
Red	Busulfan		1,6		Jul-24	
Red	C1 Esterase inhibitor		1,6	Acute hereditary angioedema	Jul-24	
Red	Cabazitaxel		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Cabazitaxel NICE Information</a>
Red	Cabotegravir		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Cabotegravir NICE information</a>
Red	Cabozantinib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Cabozantinib NICE Information</a>
Red	Calcitonin (salmon)		1,6	Hypercalcaemia, Pagets disease, Bone pain in neoplastic disease, postmenopausal osteoporosis	Jul-24	

Red	Calcium Chloride injection		1,6	Emergency Treatment of Poisoning (calcium channel blockers or systemic effects of hydrofluoric acid)	Jul-24		
Red	Calcium Folate		1,6		Jul-24		
Red	Calcium Gluconate		1,6		Jul-24		
Red	Calcium Polystyrene Sulfonate		1	All licensed indications	Feb-26		
Red	Canakinumab		1,6	NHSE Commissioned	Jul-24		
Red	Cannabidiol		1,6	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
Red	Cannabinoids		1	In line with positive NICE TA recommendations	Dec-23		<a href="#">Cannabidiol NICE information</a>
Red	Capecitabine		1,6	In line with positive NICE TA recommendations	Jul-24		<a href="#">Capecitabine NICE Information</a>
Red	Capivasertib ( in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jun-25		<a href="#">Capivasertib NICE Information</a>
Red	Caplacizumab		1,6	In line with positive NICE TA recommendations	Jul-24		<a href="#">Caplacizumab NICE Information</a>
Red	Capreomycin			Tuberculosis	Aug-24		
Red	Capsaicin Patch	Qutenza®	1	Peripheral neuropathic pain	Sep-23		
Red	Carbetocin		1,6	Uterine atony and postpartum haemorrhage after Caesarian section(prevention of)	Jul-24		
Red	Carboplatin		1,6	In line with positive NICE TA recommendations	Jul-24		
Red	Carboprost		1,6	Post-partum haemorrhage	Jul-24		
Red	Carfilzomib		1,6	In line with positive NICE TA recommendations	Jul-24		
Red	Carglumic acid		1,6	Drugs used in metabolic disorders	Jul-24		
Red	Cariprazine		1	Antipsychotic	Feb-24		
Red	Carmustine		1,6	In line with positive NICE TA recommendations	Jul-24		<a href="#">Carmustine NICE Information</a>

Red	Carnitine		1,6	Carnitine deficiency	Jul-24	
Red	Caspofungin		1,6	Antifungal	Jul-24	
Red	Catridecacog		1,6	Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and treatment of breakthrough bleeding episodes during regular prophylaxis	Jul-24	
Red	Cefazolin		1,6	Treatment of skin/soft tissue infections and bone/joint infections	Jul-24	
Red	Cefepime		1,6	Treatment of infections caused by bacteria that are cefepime-sensitive	Jul-24	
Red	Cefepime + enmetazobactam		1	Antibiotic	Aug-24	
Red	Cefiderocol		1,6	Infections due to aerobic Gram-negative organisms	Jul-24	
Red	Cefixime		1	Antibacterial	Feb-24	
Red	Cefoxitin		1,6	Antibiotic	Jul-24	
Red	Ceftaroline fosamil		1,6	Infection - complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP) in adults	Jul-24	
Red	Ceftazidime (including in combination with other drugs)		1	Antibiotic	Aug-24	
Red	Ceftobiprole		1,	Antibiotic	Aug-24	
Red	Ceftolozane (including in combination with other drugs)		1,	Antibiotic	Aug-24	
Red	Cefuroxime eye drops and injections		1	Miscellaneous ophthalmic preparations	Aug-24	

<b>Red</b>	Cemiplimab		1,6	In line with positive NICE TA recommendations	Dec-25		<a href="#">Cemiplimab NICE Information</a>
<b>Red</b>	Cenobamate (in children only )		7	Epilepsy	May-24		
<b>Red</b>	Ceritinib		1,6	In line with positive NICE TA recommendations	Aug-24		<a href="#">Ceritinib NICE information</a>
<b>Red</b>	Certolizumab		1,6	In line with positive NICE TA recommendations	Aug-24		<a href="#">Certolizumab NICE Information</a>
<b>Red</b>	Cetrorelix		1	Treatment of female infertility	Aug-24		
<b>Red</b>	Cetuximab		1,6	In line with positive NICE TA recommendations	Aug-24		<a href="#">Cetuximab NICE Information</a>
<b>Red</b>	Chlorambucil		1		Aug-24		
<b>Red</b>	Chloramphenicol (oral or injectables)		1		Aug-24		
<b>Red</b>	Chlormethine hydrochloride		1,6		Aug-24		
<b>Red</b>	Chloroquine			For malaria prophylaxis is grey, for treatment of malaria and other indications is red.	Aug-24		
<b>Red</b>	Chlorothiazide		1,6	Unlicensed special. Used in BHNFT (paediatrics)	Aug-24		
<b>Red</b>	Chorionic Gonadotrophin		1,6	Infertility.	Aug-24		
<b>Red</b>	Cidofovir		1,6	Cytomegalovirus infection in immunocompromised patients	Aug-24		
<b>Red</b>	Cipaglicosidase alfa		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Cipaglicosidase NICE information</a>
<b>Red</b>	Ciprofloxacin eye drops		1	Miscellaneous ophthalmic preparations	Aug-24		
<b>Red</b>	Cisplatin		1,6	In line with positive NICE TA recommendations	Aug-24		<a href="#">Cisplatin NICE Information</a>
<b>Red</b>	Cladribine (all formulations)		1,6	In line with positive NICE TA recommendations	Aug-24		<a href="#">Cladribine NICE information</a>

Red	Clobazam		1	Anxiety (severe- short-term relief)	Feb-26	
Red	Clofarabine		1,6	Acute lymphoblastic leukaemia	Aug-24	
Red	Clofazimine		1,6	Leprosy	Aug-24	
Red	Clozapine				Dec-25	
Red	Cobicistat (including combinations)		1,6	NHSE commissioned.	Aug-24	
Red	Co-careldopa intestinal gel	Duodopa®	1,6	Parkinson's Disease	Jul-23	
Red	Conestat alfa		1,6	Angioedema (hereditary)	Aug-24	
Red	Copper histidinate injections	Copper histidinate injections	1	Presymptomatic neonates with classical Menkes disease	May-26	
Red	Crisantaspace		1,6	Acute lymphoblastic leukaemia	Aug-24	
Red	Crizotinib		1,6	In line with positive NICE TA recommendations	Aug-24	<a href="#">Crizotinib NICE Information</a>
Red	Crovalimab		1,6	In line with positive NICE TA recommendations	Feb-25	<a href="#">Crovalimab NICE Information</a>
Red	Cyclophosphamide		1,6	Cancer chemotherapy	Aug-24	
Red	Cycloserine		1		Aug-24	
Red	Cyproheptadine		1	Emergency Treatment of Poisoning (Serotonin Syndrome)	Aug-24	
Red	Cytarabine (including in combination with other drugs)		1		Aug-24	
Red	Dabrafenib (including in combination with other drugs )		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Dabrafenib NICE information</a>
Red	Dacomitinib		1,6	In line with positive NICE TA recommendations	Oct-24	<a href="#">Dacomitinib NICE information</a>
Red	Dactinomycin		1,6	Paediatric cancers	Oct-24	
Red	Dalbavancin		1,6	Glycopeptide antibacterial	Oct-24	

<b>Red</b>	Danicopan with ravulizumab or eculizumab		1,6	In line with positive NICE TA recommendations	Nov-24		<a href="#">Danicopan NICE Information</a>
<b>Red</b>	Dapsone (dual classification)		1	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		
<b>Red</b>	Daptomycin		1	Lipopeptide antibacterial	Oct-24		
<b>Red</b>	Daratumumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23		<a href="#">Daratumumab NICE information ( also used with dexamethasone and Lenalidomide)</a>
<b>Red</b>	Darcarbazine		1	Melanoma,Soft-tissue sarcomas,Hodgkin's disease	Oct-24		
<b>Red</b>	Darolutamide (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-24		<a href="#">Darolutamide NICE Information</a>
<b>Red</b>	Darunavir (including in combination)		1	HIV infection	Oct-24		
<b>Red</b>	Dasabuvir		1,6	Chronic hepatitis C	Nov-24		
<b>Red</b>	Dasatinib		1,6	In line with positive NICE TA recommendations	Oct-24		<a href="#">Dasatinib NICE information</a>
<b>Red</b>	Daunorubicin		1,6	In line with positive NICE TA recommendations	Oct-24		<a href="#">Daunorubicin NICE Information</a>
<b>Red</b>	Deferasirox		1	Iron overload	Oct-24		
<b>Red</b>	Deferiprone		1	Iron overload in patients with thalassaemia major	Oct-24		
<b>Red</b>	Delafloxacin		1,6	Fluoroquinolone antibiotic	Apr-25		
<b>Red</b>	Delamanid		2	Pulmonary multi drug resistant TB	Nov-24		
<b>Red</b>	Delgocitinib		1,6	Treating moderate to severe chronic hand eczema	Dec-25		<a href="#">NICE TA1107</a>
<b>Red</b>	Denosumab 120mg injection	XGEVA	1	In line with NICE TA 549 and NICE TA265	Sep-23		<a href="#">Denosumab NICE TA549 &amp; TA 265 information</a>

Red	Dequalinium chloride vaginal tablets		1	Bacterial vaginosis	Sep-23	
Red	Deucravacitinib		1,6	Treating moderate to severe plaque psoriasis	Sep-23	
Red	Deutivacaftor + tezacaftor + vanzacaftor		1,6	Cystic fibrosis	Sep-25	<a href="#">NICE TA1085</a>
Red	Dexamethasone and levofloxacin eye drops		1	Prevention of infection associated with cataract surgery in adults	Sep-23	
Red	Digoxin specific antibody fragments		1,6	Management of digoxin toxicity	Apr-25	
Red	Diloxanide		1,6	Antiprotozoal drugs - amoebicides	Apr-25	
Red	Dimethyl fumarate		1,6	In line with positive NICE TA recommendations	Apr-25	<a href="#">Dimethyl+fumarate NICE information</a>
Red	Dinoprostone		1,6	Induction of labour	Apr-25	
Red	Dinutuximab		1,6	In line with positive NICE TA recommendations	Apr-25	<a href="#">Dinutuximab NICE Information</a>
Red	Diroximel		1,6	Multiple sclerosis (MS) relapsing-remitting	Apr-25	
Red	Disodium Pamidronate		1,6	Hypercalcaemia, Paget's Disease	Apr-25	
Red	Disopyramide		1,6	All licensed indications	Mar-26	
Red	Dobutamine		1,6	Inotropic Sympathomimetics	Apr-25	
Red	Docetaxel		1,6	In line with positive NICE TA recommendations	Apr-25	<a href="#">Docetaxel NICE Information</a>
Red	Dolutegravir (including combinations)		1,6	HIV	Apr-25	
Red	Doravirine (including in combination)		1,6	HIV	May-25	
Red	Dornase alfa		1,6		Jul-24	
Red	Dostarlimab		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Dostarlimab NICE Information</a>

Red	Doxapram Hydrochloride		1,6	Postoperative respiratory depression/Acute respiratory failure	May-25	
Red	Doxorubicin		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Doxorubicin NICE Information</a>
Red	Dronedaron		1	Atrial fibrillation		<a href="#">NICE TA197</a>
Red	Droperidol		1	Prevention and treatment of postoperative nausea and vomiting	May-25	
Red	Dupilumab (Dual traffic light status)		1,6	In line with positive NICE TA recommendations (refer to grey entry for use in line with NICE TA1142)	Feb-24	<a href="#">Dupilumab NICE information</a>
Red	Durvalumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Durvalumab NICE information also used in combination with other drugs</a>
Red	Eculizumab		1,6	In line with positive NICE TA recommendations	Apr-24	<a href="#">Eculizumab NICE Information</a>
Red	Efanesoctocog alfa			Treatment and prophylaxis of bleeding in patients aged $\geq 2$ years with severe or moderate haemophilia A ( $\leq 5\%$ endogenous plasma factor VIII activity)	May-25	<a href="#">NICE TA1051</a>
Red	Efavirenz (including in combination)		1,6	HIV	May-25	
Red	Efmoroctocog alfa		1,6	Used to treat bleeding disorders	May-25	
Red	Eladocagene exuparvovec		1,6	Treatment of patients aged $\geq 18$ months with a clinical, molecular and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase deficiency with a severe phenotype	Dec-23	

Red	Elafibranor		1,6	for previously treated primary biliary cholangitis	Dec-24	
Red	Elbasvir-grazoprevir		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Elbasvir-grazoprevir NICE information</a>
Red	Elosulfase alfa		1,6	Mucopolysaccharidosis type 4A	May-25	<a href="#">Elosulfase+alfa NICE Information</a>
Red	Elranatamab		1,6	In line with positive NICE TA recommendations	Jan-25	<a href="#">Elranatamab NICE Information</a>
Red	Eltrombopag olamine		1	Treating chronic immune thrombocytopenia in adults	Sep-23	<a href="#">NICE TA293</a>
Red	Elvitegravir (including combinations)		1,6	HIV	May-25	
Red	Emicizumab		1,6	Prophylaxis of haemorrhage in haemophilia A	May-25	
Red	Emtricitabine (including combinations)		1,6	HIV	May-25	
Red	Encorafenib		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Encorafenib NICE Information</a>
Red	Enfortumab vedotin (including combinations)		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Enfortumab+vedotin NICE Information</a>
Red	Enfuvirtide		1,6	HIV	May-25	
Red	Entecavir		1,6	In line with recommended NICE TA's	Jun-25	<a href="#">Entecavir NICE Information</a>
Red	Entrectinib		1,6	In line with recommended NICE TA's	Jun-25	<a href="#">Entrectinib NICE information</a>
Red	Enzalutamide		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Enzalutamide NICE information</a>
Red	Epcoritamab		1,6	In line with positive NICE TA recommendations	Apr-24	<a href="#">Epcoritamab NICE Information</a>
Red	Ephedrine 30mg/10ml and 30mg/ml injection		1	Vasoconstrictor Sympathomimetics	Jun-25	
Red	Epirubicin		1	Cancer - breast (Advanced or metastatic) Cancer - Colorectal (metastatic)	Jun-25	
Red	Eplontersen		1,6	In line with positive NICE TA recommendations	Jan-25	<a href="#">Eplontersen NICE Information</a>

Red	Epoetin Alfa		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25	<a href="#">Epoetin alfa NICE information</a>
Red	Epoetin Beta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25	<a href="#">Epoetin Beta NICE information</a>
Red	Epoetin Zeta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25	-
Red	Epoprostenol		1,6	pulmonary arterial hypertension, to prevent blood clotting during kidney dialysis in emergency situations	Jul-25	
Red	Eptacog alfa (activated)	(NovoSeven®)	1,6	Treatment of severe postpartum haemorrhage	Jun-25	
Red	Eptacog beta	(Cevenfacta®) (activated)	1,6	Treatment of bleeding episodes and for the prevention of bleeding: in patients with congenital haemophilia	Jun-25	
Red	Eptifibatide		1	In line with recommended NICE TA's	Jun-25	<a href="#">Eptifibatide NICE information</a>
Red	Eptinezumab		1	Migraine	Sep-23	<a href="#">NICE TA871</a>
Red	Eravacycline	(Xerava®)	1	Complicated intra-abdominal infections in adults	Jun-25	
Red	Erdafitinib		1,6	In line with recommended NICE TA's	Jun-25	<a href="#">Erdafitinib NICE Information</a>
Red	Erenumab		1,3	Migraines in adults		<a href="#">NICE TA682</a>
Red	Ergometrine		1	Postpartum haemorrhage caused by uterine atony	Jun-25	
Red	Eribulin		1,6	In line with recommended NICE TA's	Jun-25	<a href="#">Eribulin NICE information</a>
Red	Erlotinib		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Erlotinib NICE information</a>
Red	Ertapenem		1	Carbapenems	Jun-25	

<b>Red</b>	Esketamine solution for injection/infusion		1	Anaesthesia and pain relief (analgesia)	Jun-25	
<b>Red</b>	Eslicarbazepine ( in children only)		7	Epilepsy	May-24	
<b>Red</b>	Esmolol	(Brevibloc®)	1	Beta-adrenoceptor blocking drugs	Jun-25	
<b>Red</b>	Etanercept		1,6	In line with recommended NICE TA's	Jul-25	<a href="#">Etanercept NICE information</a>
<b>Red</b>	Etelcalcetide		1	In line with recommended NICE TA's	Jul-25	<a href="#">Etelcalcetide NICE information</a>
<b>Red</b>	Etoposide		1	In line with recommended NICE TA's	Jul-25	<a href="#">Etoposide NICE information</a>
<b>Red</b>	Etranacogene dezaparvovec		1,6	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B	Oct-24	
<b>Red</b>	Etrasimod		1,6	moderately to severely active ulcerative colitis in people aged 16 and over	Jun-24	
<b>Red</b>	Etravirine		1,6	HIV infection.	Jul-25	
<b>Red</b>	European Viper Venom Antiserum		1	European Adder bite	Jul-25	
<b>Red</b>	Everolimus		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Everolimus NICE information</a>
<b>Red</b>	Evolocumab		1,6	In line with recommended NICE TA's	Jul-25	<a href="#">Evolocumab NICE information</a>
<b>Red</b>	Ex vivo expanded autologous human corneal epithelial cells containing stem cells	(Holoclar®)	1,6	In line with recommended NICE TA's	Jul-25	<a href="#">Holoclar NICE information</a>
<b>Red</b>	Exagamglogene autotemcel		1,6	In line with positive NICE TA recommendations	Oct-24	<a href="#">Exagamglogene+autotemcel NICE Information</a>
<b>Red</b>	Ezetimibe in children		7	Statin	Feb-24	

Red	Factor VIIa, Factor VIII, Factor IX, Factor XIII		1,6	Haemorrhage in patients with haemophilia A or B with antibodies to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann's thrombasthenia	Jul-25		
Red	Faricimab		1,6	In line with positive NICE TA recommendations	Oct-24		<a href="#">Faricimab NICE Information</a>
Red	Fedratinib		1,6	In line with recommended NICE TA's	Jul-25		<a href="#">Fedratinib NICE information</a>
Red	Felbamate		1	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
Red	Fenfluramine		1,6	In line with positive NICE TA recommendations	May-25		<a href="#">Fenfluramine NICE Information</a>
Red	Ferric carboxymaltose		1	Iron deficiency when oral iron preparations are ineffective or cannot be used.	Jul-25		
Red	Fezolinetant		1,6	Treating moderate to severe vasomotor symptoms associated with menopause	May-26		<a href="#">NICE TA 1143</a>
Red	Fibrin sealants		1	Treatment and prophylaxis of haemorrhage	Jul-25		
Red	Fibrinogen		1,6	As per BCSH guidelines for specialist indications	Jul-25		
Red	Filgotinib		1	In line with recommended NICE TA's	Jul-25		<a href="#">Filgotinib NICE information</a>
Red	Filgrastim		1	Neutropenia	Jul-25		
Red	Fingolimod		1,6	In line with recommended NICE TA's	Jul-25		<a href="#">Fingolimod NICE information</a>
Red	Fludarabine		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Fludarabine NICE information</a>
Red	Fluocinolone acetonide		1,6	Chronic diabetic macular oedema	Apr-24		

<b>Red</b>	Fluocinolone acetonide intravitreal implant	(Iluvien®)	1	In line with recommended NICE TA's	Jul-25		<a href="#">Fluocinolone acetonide intravitreal implant NICE information</a>
<b>Red</b>	Fluoride tablets		6	Dental indications	Sep-23		
<b>Red</b>	Follitropin alfa, beta, delta & Follitropin alfa/lutropin alfa		1	IVF	Jul-25		
<b>Red</b>	Fomepizole		1	Emergency Treatment of Poisoning (ethylene glycol or methanol poisoning)	Jul-25		
<b>Red</b>	Fondaparinux		1	Acute coronary syndromes, NSTEMI, angina	Jul-25		
<b>Red</b>	Fosamprenavir		1,6	HIV infection.	Jul-25		
<b>Red</b>	Fosaprepitant		1	Chemotherapy-associated nausea and vomiting	Aug-25		
<b>Red</b>	Foslevodopa–foscarbidopa		1,6	Advanced Parkinson's with motor symptoms	Feb-24		<a href="#">NICE Information</a>
<b>Red</b>	Fostamatinib		1	Treating refractory chronic immune thrombocytopenia	Aug-25		<a href="#">NICE TA 835</a>
<b>Red</b>	Fostemsavir		1,6	HIV in combination with other anti-retroviral drugs	Aug-25		
<b>Red</b>	Fremanezumab		1	As per licenced appropriate NICE TA	Sep-23		<a href="#">Fremanezumab NICE information</a>
<b>Red</b>	Fruquintinib		1,6	Previously treated metastatic colorectal cancer	Aug-25		<a href="#">NICE TA 1079</a>
<b>Red</b>	Fulvestrant		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Fulvestrant NICE information</a>

<b>Red</b>	Futibatinib		1,6	Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy	Jan-26	<a href="#">Futibatinib NICE Information</a>
<b>Red</b>	Galcanezumab		1	Migraine prevention	Aug-25	<a href="#">NICE TA659</a>
<b>Red</b>	Galsulfase		1,6	Mucopolysaccharidosis	Aug-25	
<b>Red</b>	Ganciclovir eye drops		1,6	All licensed indications	Mar-26	
<b>Red</b>	Garadacimab		1,6	Preventing recurrent attacks of hereditary angioedema in people 12 years and over	Nov-25	<a href="#">NICE TA1101</a>
<b>Red</b>	Gefitinib		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Gefitinib NICE information</a>
<b>Red</b>	Gelatin	(Gelaspan®)	1,5	Plasma substitute	Apr-26	
<b>Red</b>	Gemcitabine		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Gemcitabine NICE information</a>
<b>Red</b>	Gemtuzumab		1,6	Untreated acute myeloid leukaemia (AML)	Aug-25	<a href="#">NICE TA545</a>
<b>Red</b>	Gilteritinib		1,6	Treatment of relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.	Aug-25	<a href="#">NICE TA642</a>
<b>Red</b>	Glatiramer		1,6	Multiple Sclerosis	Aug-25	<a href="#">NICE TA527</a>
<b>Red</b>	Glecaprevir/Pibrentasvir		1,6	Chronic hepatitis C	Aug-25	<a href="#">NICE TA499</a>
<b>Red</b>	Glibenclamide suspension	Amglidia®	1	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.	May-26	
<b>Red</b>	Glofitamab		1,6	In line with positive NICE TA recommendations	Nov-23	<a href="#">Glofitamab NICE Information</a>

Red	Glucarpidase		1,6	To reduce toxic plasma methotrexate concentration in adults and children (aged ≥28 days) with delayed methotrexate elimination	Dec-23	
Red	Golimumab		1	In line with recommended NICE TAs	Aug-25	<a href="#">Golimumab NICE information</a>
Red	Green Tea Leaves extract ointment (Camellia sinensis)		1,6	Warts - genital and perianal	Jul-24	
Red	Guselkumab		1,6	In line with positive NICE TA recommendations	Aug-25	<a href="#">Guselkumab NICE Information</a>
Red	Human coagulation factor VIII, human Von Willebrand factor		1,6	Haemophilia A and Von Willebrand disease- prevention and treatment of bleeding	Sep-25	
Red	Human coagulation factor X		1,6	Prophylaxis of bleeding in patients with hereditary factor X deficiency	Sep-25	
Red	Human hepatitis B immunoglobulin		1	All licenced indications	Sep-25	
Red	Human Menopausal Gonadotrophins (Menotrophin)		1	All licensed indications	Sep-25	
Red	Human normal immunoglobulin		1,6	Multiple indications	Sep-25	<a href="#">Immunoglobulin supporting information</a>
Red	Hybrid closed loop systems		1,6	Managing blood glucose levels in type 1 diabetes	Feb-24	
Red	Hydroxocobalamin (dual traffic light)		1	Emergency Treatment of Poisoning (cyanide)	Sep-25	
Red	Hydroxycarbamide		1	All licensed indications	Sep-25	
Red	Ibrutinib		1,6	In line with positive NICE TA recommendations	Oct-23	<a href="#">Ibrutinib NICE information</a>
Red	Icatibant		1,6	Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency	Sep-25	

Red	Idarubicin		1	Acute non-lymphocytic leukaemia, advanced breast cancer. Acute myeloid leukaemia in children , in combination with cytarabine, for remission induction.	Sep-25	
Red	Idarucizumab		1	Rapid reversal of anticoagulant effect of dabigatran	Sep-25	
Red	Idebenone		1,6	Visual impairment in patients with Leber's Hereditary Optic Neuropathy (LHON)	Sep-25	<a href="#">NICE TA1093</a>
Red	Idelalisib		1	In line with positive NICE TA recommendations	Oct-23	<a href="#">Idelalisib NICE information</a>
Red	Idursulfase		1,6	Hunter syndrome (Mucopolysaccharidosis II)	Sep-25	
Red	Iloprost		1	All licensed indications	Sep-25	
Red	Imatinib		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Imatinib NICE information</a>
Red	Imiglucerase		1,6	Drugs used in metabolic disorders/Gauchers disease	Sep-25	
Red	Imlifidase		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Imlifidase NICE information</a>
Red	Infliximab (including biosimilar)		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Infliximab NICE information</a>
Red	Inosine pranobex		1	Herpes simplex	Sep-25	
Red	Inotersen		1,6	In line with positive NICE recommendations	Sep-25	<a href="#">Inotersen NICE information</a>
Red	Interferon Alfa, Beta 1a & 1b,		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Interferon NICE information</a>
Red	Ipilimumab		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Ipilimumab NICE information</a>
Red	Iptacopan		1,6	Paroxysmal nocturnal haemoglobinuria	Oct-24	<a href="#">Iptacopan NICE Information</a>

Red	Isatuximab( including in combination)		1,6	In line with positive NICE TA recommendations	Sep-25		<a href="#">Isatuximab NICE information</a>
Red	Isavuconazole		1,6	Invasive aspergillosis. Mucormycosis	Sep-25		
Red	Isocarboxazid		1	Depressive illness	Sep-25		
Red	Isoprenaline Sulfate		1	Inotropic Sympathomimetics	Sep-25		
Red	Isosorbide dinitrate injection		1,5	Emergency Treatment of Poisoning (hypertension)	Apr-26		
Red	Isotretinoin		1	Acne	Sep-25		
Red	ITULAZAX 12 SQ-Bet		7	Moderate-to-severe allergic rhinitis and/or conjunctivitis allergen extract of pollen from white birch	Sep-25		<a href="#">NICE TA1087</a>
Red	IV nutrition products		1,5	Intravenous nutrition	Apr-26		
Red	Ivacaftor–tezacaftor–elixacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor			In line with positive NICE TA recommendations	Oct-24		<a href="#">NICE TA988</a>
Red	Ivermectin 3mg tablets (dual traffic light status)		1	Red Traffic Light Status for all other indications Green for scabies treatment	Nov-24		
Red	Ivosidenib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Ivosidenib NICE information</a>
Red	Ixazomib		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Ixazomib NICE information</a>
Red	Ixekizumab		1	In line with positive NICE TA recommendations	Oct-25		<a href="#">Ixekizumab NICE information</a>
Red	Ketamine		1,6	All licensed indications	Mar-26		<a href="#">Ketamine BNF Information</a>
Red	Ketoconazole tablets		1	Cushing's syndrome	Oct-23		
Red	Lamivudine		1	For all indications	Oct-25		
Red	Lanadelumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Lanadelumab NICE information</a>

<b>Red</b>	Landirolol hydrochloride		1,5	Supraventricular tachycardia and for the rapid control of ventricular rate	Apr-23	
<b>Red</b>	Lanreotide		1,6	All licensed indications	Mar-26	<a href="#">Lanreotide BNF Information</a>
<b>Red</b>	Lanthanum		1	In line with NICE guidance	Oct-25	<a href="#">Lanthanum NICE information</a>
<b>Red</b>	Lapatinib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Lapatinib NICE information</a>
<b>Red</b>	Laronidase		1,6	Mucopolysaccharidosis	Oct-25	
<b>Red</b>	Larotrectinib sulphate		1,6	In line with positive NICE TA recommendations	Oct-23	<a href="#">Larotrectinib NICE information</a>
<b>Red</b>	Lebrikizumab		1,6	In line with positive NICE TAs	Aug-24	<a href="#">Lebrikizumab NICE Information</a>
<b>Red</b>	Ledipasvi/Sofosbuvir		1,6	Hepatitis C	Oct-25	
<b>Red</b>	Lenacapavir		1,6	HIV infection	Sep-23	
<b>Red</b>	Lenalidomide		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Lenalidomide NICE information</a>
<b>Red</b>	Leniolisib		1,6	Treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	May-25	<a href="#">NICE HST33</a>
<b>Red</b>	Lenograstim		1	All licensed indications	Oct-25	
<b>Red</b>	Lenvatinib		1	In line with positive NICE TA recommendations	Sep-23	<a href="#">Lenvatinib NICE information</a>
<b>Red</b>	Letermovir		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Letermovir NICE information</a>
<b>Red</b>	Levocarnitine		1	All licensed indications	Oct-25	<a href="#">Lenograstim BNF Information</a>

Red	Levodopa + carbidopa + entacapone	Lecigon®	1,6	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results	Dec-24	
Red	Levofloxacin- Infusion, solution for infusion, nebuliser liquid & eye drops		1,6	All licensed indications	Mar-26	<a href="#">Levofloxacin BNF Information</a>
Red	Levothyroxine injection		1	Myxoedema coma and hypothyroidism in patients where oral therapy is not feasible, particularly due to difficulties in swallowing or malabsorption	Dec-23	
Red	Linzagolix		1	In line with positive NICE TA recommendations	Jul-25	<a href="#">Linzagolix NICE Information</a>
Red	Lipegfilgrastim		1	All licensed indications	Oct-25	
Red	Liraglutide	Saxenda®	1,6	Weight loss	Oct-23	<a href="#">NICE TA664</a>
Red	Lisocabtagene maraleucel		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Lisocabtagene+maraleucel NICE Information</a>
Red	Lomitapide		1	An inhibitor of microsomal triglyceride transfer protein (MTP)	Oct-23	
Red	Lomustine		1	All licensed indications	Oct-25	
Red	Loncastuximab tesirine		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Loncastuximab+tesirine NICE information</a>
Red	Lopinavir/Ritonavir		1	All licensed indications	Oct-25	
Red	Lorlatinib		1,6	In line with positive NICE TA recommendations	Sep-23	<a href="#">Lorlatinib NICE information</a>
Red	Loteprednol eye drops		1	Corticosteroid eye drops	May-26	

Red	L-Tryptophan		1,5	Adults with treatment-resistant depression following unsuccessful trial of standard antidepressants and as an adjunct to other antidepressant medications	May-24	
Red	Lumacaftor/Ivacaftor		1,6	Treatment for cystic fibrosis	Oct-24	<a href="#">Lumacaftor/Ivacaftor NICE Information</a>
Red	Lumasiran		1,6	Treatment of primary hyperoxaluria type 1 in all age groups	Sep-23	
Red	Lurasidone		1	All licensed indications	Oct-25	
Red	Lusutrombopag		1	In line with positive NICE TA recommendations	Oct-25	<a href="#">Lusutrombopag NICE information</a>
Red	Macitentan		1,6	All licensed indications	Oct-25	
Red	Mannitol		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Mannitol NICE information</a>
Red	Maraviroc		1,6	All licensed indications	Oct-25	
Red	Maribavir		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Maribavir NICE information</a>
Red	Marstacimab		1	Routine prophylaxis of bleeding episodes in patients with haemophilia	Aug-25	<a href="#">NICE TA1073</a>
Red	Mavacamten		1,6	Treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3	Oct-23	<a href="#">NICE TA913</a>
Red	Mecasermin		1	All licensed indications	Oct-25	
Red	Mepacrine		1	All licensed indications	Oct-25	
Red	Mepolizumab		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Mepolizumab NICE information</a>
Red	Mercaptamine		1,6	All licensed indications	Oct-25	
Red	Meropenem		1	All licensed indications	Oct-25	
Red	Mesna		1	All licensed indications	Oct-25	
Red	Methoxyflurane		1	All licensed indications	Oct-25	

Red	Methsuximide		1	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
Red	Metreleptin		1,6	In line with NICE recommendations	Oct-25		<a href="#">Metreleptin NICE information</a>
Red	Metyrapone		1,6	Cushing's syndrome	Jun-24		
Red	Mexiletine		1,6	All licensed indications	Oct-25		<a href="#">Mexiletine NICE information</a>
Red	Midostaurin		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Midostaurin NICE information</a>
Red	Mifamurtide		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Mifamurtide NICE information</a>
Red	mifepristone (includes in combination)		1	All licensed indications	Oct-25		
Red	Migalastat		1,6	In line with NICE recommendations	Oct-25		<a href="#">Migalastat NICE information</a>
Red	Miglustat		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Miglustat information</a>
Red	Mirikizumab		1,6	In line with positive NICE TA recommendations	Aug-25		<a href="#">Mirikizumab NICE Information</a>
Red	Misoprostol (includes in combination)(multiple traffic light classifications)		1	Induction of labour or miscarriage or abortion	Oct-25		
Red	Mitomycin		1	All licensed indications	Oct-25		
Red	Mitotane		1	All licensed indications	Oct-25		
Red	Mitoxantrone		1	All licensed indications	Oct-25		
Red	Mogamulizumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Mogamulizumab NICE information</a>
Red	Molnupiravir		1	Treating COVID-19	May-25		<a href="#">NICE TA1056</a>
Red	Momelotinib		1,6	Myelofibrosis-related splenomegaly or symptoms	May-24		
Red	Morphine Sulphate 100 microgram/ml oral solution		1	Opioid	Oct-23		

<b>Red</b>	Mycophenolate (dual traffic light classification)		1	Red for all other indications and TLS Amber for shared care protocols	Aug-24	
<b>Red</b>	Natalizumab		1,6	In line with positive NICE TA recommendations	Nov-23	<a href="#">Natalizumab NICE information</a>
<b>Red</b>	Nelfinavir		1,5,6	HIV	Oct-25	
<b>Red</b>	Nemolizumab		1,6	Moderate to severe atopic dermatitis in people 12 years and over	Aug-25	<a href="#">NICE TA1077</a>
<b>Red</b>	Nepafenac		1	All licensed indications	Oct-25	
<b>Red</b>	Neratinib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Neratinib NICE information</a>
<b>Red</b>	Nevirapine		1,6	All licensed indications	Oct-25	
<b>Red</b>	Nilotinib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Nilotinib NICE information</a>
<b>Red</b>	Nimodipine		1	All licensed indications	Oct-25	
<b>Red</b>	Nintedanib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Nintedanib NICE information</a>
<b>Red</b>	Niraparib		1,6	In line with positive NICE TA recommendations	Mar-26	<a href="#">Niraparib NICE Information</a>
<b>Red</b>	Nirmatrelvir plus Ritonavir	Paxlovid®	1,3	COVID-19 Treatment	Jun-23	
<b>Red</b>	Nirmatrelvir plus ritonavir and tocilizumab		1,5	for treating COVID-19	Apr-26	
<b>Red</b>	Nirsevimab		1,6	Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season	Nov-25	
<b>Red</b>	Nitisinone		1,6	All licensed indications	Oct-25	

<b>Red</b>	Nivolumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Nivolumab NICE Information</a>
<b>Red</b>	Noradrenaline		1	All licensed indications	Oct-25		
<b>Red</b>	Nusinersen		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Nusinersen NICE information</a>
<b>Red</b>	Obecabtagene autoleucel		1,6	Relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in line with positive NICE TA	Jan-26		<a href="#">Obecabtagene autoleucel NICE Information</a>
<b>Red</b>	Obeticholic acid		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Obeticholic acid NICE information</a>
<b>Red</b>	Obinutuzumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Obinutuzumab NICE information</a>
<b>Red</b>	Ocrelizumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Ocrelizumab NICE information</a>
<b>Red</b>	Ofatumumab		1	In line with positive NICE TA recommendations	Nov-23		<a href="#">Ofatumumab NICE information</a>
<b>Red</b>	Olaparib (can be given with bevacizumab & abiraterone)		1,6	In line with positive NICE TA recommendations	Sep-23		<a href="#">Olaparib NICE information</a>
<b>Red</b>	Omalizumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Omalizumab NICE information</a>
<b>Red</b>	Ombitasvir, paritaprevir and ritonavir		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Ombitasvir/paritaprevir/ritonavir NICE information</a>
<b>Red</b>	Osimertinib		1,6	In line with positive NICE TA recommendations	Apr-25		<a href="#">Osimertinib NICE Information</a>
<b>Red</b>	Oxaliplatin		1	In line with positive NICE TA recommendations	Oct-25		<a href="#">Oxaliplatin NICE information</a>

Red	Oxybutynin intravesical solution		6	Indicated for the suppression of neurogenic detrusor overactivity (NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics.	Aug-24		
Red	Oxytocin (includes in combination)		1	All licensed indications	Oct-25		
Red	Ozanimod		1	In line with positive NICE TA recommendations	Nov-23		<a href="#">Ozanimod NICE information</a>
Red	Paclitaxel		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Paclitaxel NICE information</a>
Red	Palbociclib		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Palbociclib NICE information</a>
Red	Palonosetron		1,6	All licensed indications	Oct-25		
Red	Panitumumab		1,6	In line with positive NICE TA recommendations	Dec-23		<a href="#">Panitumumab NICE information</a>
Red	Panobinostat		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Panobinostat NICE information</a>
Red	Paracetamol + ibuprofen solution for infusion		1	Use in adults for the short-term symptomatic treatment of acute moderate pain and the reduction of fever, where an intravenous route of administration is considered clinically necessary and/or when other routes of administration are not possible	Feb-24		
Red	Paraldehyde		1	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
Red	Paricalcitol		1,6	All licensed indications	Oct-25		

<b>Red</b>	Pasireotide		1,6	All licensed indications	Oct-25	
<b>Red</b>	Patiomer		1	In line with positive NICE TA recommendations	Oct-25	<a href="#">Patiomer NICE information</a>
<b>Red</b>	Pazopanib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pazopanib NICE information</a>
<b>Red</b>	Pegaspargase		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pegaspargase NICE information</a>
<b>Red</b>	Pegfilgrastim (including biosimilars)		1	All licensed indications	Oct-25	
<b>Red</b>	Peginterferon (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Peginterferon NICE information</a>
<b>Red</b>	Pegunigalsidase alfa		1,6	Fabry disease	Nov-23	<a href="#">NICE Pegunigalsidase+alfa information</a>
<b>Red</b>	Pegvisomant		1,6	All licensed indications	Oct-25	
<b>Red</b>	Pegzilarginase		1,5	In line with positive NICE TA recommendations	Apr-26	<a href="#">Pegzilarginase NICE information</a>
<b>Red</b>	Pembrolizumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23	<a href="#">Pembrolizumab NICE information</a>
<b>Red</b>	Pemetrexed		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pemetrexed NICE information</a>
<b>Red</b>	Pemigatinib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pemigatinib NICE information</a>
<b>Red</b>	Pentamidine		1	All licensed indications	Oct-25	
<b>Red</b>	Pentosan		1	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pentosan NICE information</a>
<b>Red</b>	Pentostatin		1	Hairy cell leukaemia	Oct-25	
<b>Red</b>	Pertuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pertuzumab NICE information</a>

<b>Red</b>	Phenylephrine + ketorolac		1	Use in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery	Aug-24	
<b>Red</b>	Phenylephrine injection		1	For all indications. See red & grey lists	Oct-25	
<b>Red</b>	Pirfenidone		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pirfenidone NICE information</a>
<b>Red</b>	Pitolisant (dual classification)		1	Narcolepsy. See also Grey for other indications	Dec-25	<a href="#">Pitolisant NICE information</a>
<b>Red</b>	Plerixafor		1,6	All licensed Indications	Oct-25	
<b>Red</b>	Polatuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Polatuzumab NICE information</a>
<b>Red</b>	Pomalidomide		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Pomalidomide NICE information</a>
<b>Red</b>	Ponatinib		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Ponatinib NICE information</a>
<b>Red</b>	Ponesimod		1,6	In line with positive NICE TA recommendations	Oct-25	<a href="#">Ponesimod NICE information</a>
<b>Red</b>	Posaconazole		1,6	All licensed indications	Oct-25	

<b>Red</b>	Potassium citrate modified-release tablet	Renodyra®	1	Use in adults for the treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones; the treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis; the treatment of renal tubular acidosis with calcium nephrolithiasis	Apr-26	
<b>Red</b>	Pretomanid		1,6	TB in >14 year olds	Nov-24	<a href="#">NHS E document</a>
<b>Red</b>	Procarbazine		1	All licensed indications	Oct-25	
<b>Red</b>	Progesterone micronised vaginal preparations (multiple traffic light classifications)		1	Supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles	May-26	<a href="#">Different products have different licensed indications - refer to the SPC.</a>
<b>Red</b>	Protamine		1	Emergency treatment of poisoning (heparin reversal)	Oct-25	
<b>Red</b>	Quizartinib		1,6	For induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Nov-24	<a href="#">NICE TA1013</a>
<b>Red</b>	Raltegravir		1,6	HIV	Oct-25	
<b>Red</b>	Ranibizumab (Branded/ biosimilar or in combination )		1,6	In line with positive NICE TA recommendations	Jun-23	<a href="#">Ranibizumab NICE information</a>
<b>Red</b>	Rasburicase		1,6	Hyperuricaemia associated with cytotoxic drugs	Oct-25	
<b>Red</b>	Ravulizumab		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Ravulizumab NICE information</a>

Red	Regorafenib		1,6	In line with positive NICE TA recommendations	Dec-23		
Red	Relugolix	Orgovyx®	1,7	Treating hormone-sensitive prostate cancer	Feb-26		<a href="#">NICE TA995</a>
Red	Relugolix–estradiol–norethisterone (Dual traffic light status)	Ryeqo®	1,3	Treating symptoms of endometriosis	May-25		<a href="#">NICE TA1057</a>
Red	Remdesivir (including in combination with other drugs)		1,3	Adults and children aged 12 years and older COVID-19 Treatment	Jun-23	Oct-25	<a href="#">Interim Clinical Commissioning Policy</a>
Red	Reslizumab		1,6	In line with positive NICE TA recommendations	Oct-25		<a href="#">Reslizumab NICE information</a>
Red	Ribavirin (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Ribavirin NICE information</a>
Red	Ribociclib		1,6	In line with positive NICE TA recommendations	Sep-25		<a href="#">Ribociclib NICE Information</a>
Red	Ribociclib (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Ribociclib NICE information</a>
Red	Rilpivirine (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Rilpivirine NICE information</a>
Red	Riociguat		1,6	All licensed indications	Nov-25		
Red	Risankizumab		1,6	In line with positive NICE TA recommendations	Oct-24		<a href="#">Risankizumab NICE Information</a>
Red	Risdiplam		1,6	In line with positive NICE TA recommendations	Dec-23		<a href="#">Risdiplam NICE Information</a>
Red	Ritlecitinib		1,6	Severe alopecia areata in people 12 years and over	May-24		
Red	Ritonavir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Ritonavir NICE information</a>
Red	Rituximab		1,6	In line with positive NICE TA recommendations	Dec-23		<a href="#">Rituximab NICE Information</a>

Red	Romiplostim		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Romiplostim NICE information</a>
Red	Romozosumab		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Romozosumab NICE information</a>
Red	Ropeginterferon		1,6	All licensed indications	Nov-25	<a href="#">Ropeginterferon NICE TA in development</a>
Red	Ropivacaine		1	All licensed indications	Nov-25	
Red	Roxadustat		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Roxadustat NICE information</a>
Red	Rucaparib		1,6	In line with positive NICE TA recommendations	May-25	<a href="#">Rucaparib NICE Information</a>
Red	Ruxolitinib		1,6	In line with positive NICE TA recommendations	Nov-23	<a href="#">NICE Ruxolitinib information</a>
Red	Sacituzumab govitecan		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Sacituzumab+govitecan NICE TA</a>
Red	Sapropterin		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Sapropterin NICE Information</a>
Red	Sarilumab		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Sarilumab NICE information</a>
Red	Sebelipase alfa (dual traffic light classification)		1,6	Wolman disease cross reference to Grey TLS	Feb-24	
Red	Secukinumab		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Secukinumab NICE information</a>
Red	Selexipag		1,6	All licensed indications	Nov-25	
Red	Selinexor		1,6	In line with positive NICE TAs(including in combination with other drugs)		<a href="#">Selinexor NICE information</a>
Red	Selpercatinib		1,6	In line with positive NICE TA recommendations	Sep-23	<a href="#">Selpercatinib NICE information</a>
Red	Semaglutide injection	Wegovy®	16	In line with positive NICE TA recommendations (Refer to Place Based Weight Management Pathways)	Sep-23	<a href="#">Semaglutide NICE information</a>

Red	Setmelanotide		1,6	For treating obesity and hyperphagia in Bardet-Biedl syndrome	Jul-24	
Red	Sevelamer		1	All licensed indications	Dec-25	
Red	Sildenafil (For Pulmonary Arterial Hypertension)	Revatio	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also sildenafil entries for Erectile Dysfunction.	May-25	<a href="#">NHS England Commissioning policy, also can be found on NHSE High Cost drugs list</a>
Red	Siponimod		1,6		Nov-25	<a href="#">Siponimod NICE information</a>
Red	Sodium Chloride oral solution		1,5	Oral sodium	Apr-26	
Red	Sodium Oxybate		1,6	Narcolepsy	Dec-23	
Red	Sodium Phenylbutyrate (Dual Classification)		1,6	All licensed indications, see also grey traffic light classification listing	Nov-25	
Red	Sodium Zirconium Cyclosilicate		7	Hyperkalaemia	Jan-24	
Red	Sofosbuvir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Sofosbuvir NICE information</a>
Red	Solriamfetol		1,6	In line with positive NICE TA recommendations	Dec-23	<a href="#">Solriamfetol NICE Information</a>
Red	Somapacitan		1	Somapacitan for treating growth hormone deficiency in people 3 to 17 years	Jul-25	<a href="#">NICE TA 1066</a>
Red	Sorafenib		1,6	In line with positive NICE TA recommendations	Dec-23	<a href="#">Sorafenib NICE Information</a>
Red	Sotorasib		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Sotorasib NICE information</a>
Red	Sotrovimab		1,3	Adults and young people aged 12 years and over Covid-19 Treatment	Jun-23	
Red	Sparsentan		1,6	In line with positive NICE TA recommendations	Sep-25	<a href="#">Sparsentan NICE Information</a>

Red	Spesolimab		1,3,6	Spesolimab for treating generalised pustular psoriasis flares	Jul-25	<a href="#">NICE TA 1070</a>
Red	Streptomycin		1	All licensed indications	Nov-25	
Red	Streptozocin		1	All licensed indications	Nov-25	
Red	Sucroferric oxyhydroxide		1,6	All licensed indications	Nov-25	
Red	Sugammadex		1	All licensed indications	Nov-25	
Red	Sunitinib		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Sunitinib NICE information</a>
Red	Tadalafil (For Pulmonary Arterial Hypertension)	Adcirca	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also Tadalafil entries for Erectile Dysfunction.	May-25	<a href="#">NHS England Commissioning policy, also can be found on NHSE High Cost drugs list</a>
Red	Tafamidis (dual traffic light combination)		1,6	In line with positive NICE TA recommendations	Jul-24	<a href="#">Tafamidis NICE Information</a> <a href="#">Also see reference to Grey traffic light status</a>
Red	Talazoparib		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Talazoparib NICE information</a>
Red	Talimogene laherparepvec		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Talimogene NICE information</a>
Red	Talquetamab		1,6	Relapsed and refractory multiple myeloma in line with positive NICE TA	Jan-26	<a href="#">Talquetamab NICE Information</a>
Red	Tazobactan ( including in combination with other drugs)		1	Antibiotic	Aug-24	
Red	Tebentafusp		1,6	In line with positive NICE TA recommendations	Feb-25	<a href="#">Tebentafusp NICE Information</a>
Red	Teclistamab		1,6	Relapsed and refractory multiple myeloma	Jun-23	<a href="#">Teclistamab NICE Information</a>
Red	Tedizolid		1	All licensed indications	Nov-25	

<b>Red</b>	Teduglutide		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Teduglutide NICE information</a>
<b>Red</b>	Tenecteplase			Treating acute ischaemic stroke	Oct-24	<a href="#">NICE TA990</a>
<b>Red</b>	Tenofovir (including in combinatin with other drugs)		1,6	HIV & also in line with positive NICE TA recommendations	Nov-25	<a href="#">Tenofovir NICE information</a>
<b>Red</b>	Tepotinib		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Tepotinib NICE information</a>
<b>Red</b>	Teriflunomide		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Teriflunomide NICE information</a>
<b>Red</b>	Teriparatide		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Teriparatide NICE information</a>
<b>Red</b>	Terlipressin		1	All licensed indications	Nov-25	
<b>Red</b>	Tetracosactide		1	All licensed indications	Nov-25	
<b>Red</b>	Tezacaftor (in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Tezacaftor NICE information</a>
<b>Red</b>	Tezepelumab		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Tezepelumab NICE information</a>
<b>Red</b>	Thalidomide		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Thalidomide NICE information</a>
<b>Red</b>	Thiamine hydrochloride injection		1	Thiamine deficiency conditions	Jan-25	
<b>Red</b>	Thiotepa		1	All licensed indications	Nov-25	
<b>Red</b>	Tigecycline		1	All licensed indications	Nov-25	
<b>Red</b>	Tildrakizumab		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Tildrakizumab NICE information</a>
<b>Red</b>	Tioguanine		1	All licensed indications	Nov-25	
<b>Red</b>	Tirofiban		1	In line with positive NICE TA recommendations	Nov-25	<a href="#">Tirofiban NICE information</a>

<b>Red</b>	Tirzepatide weight management - patients who fulfill NICE TA 1026 AND meet NHS SY Specialist Weight Management Service referral criteria [Multiple traffic light classifications]		6	For managing overweight and obesity in patients who fulfill NICE TA1026, including those in cohort one who may not want or be suitable for management in primary care AND meet NHS SY SWMS referral criteria.	May-25		<a href="#">Tirzepatide weight management Information</a>
<b>Red</b>	Tisagenlecleucel		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Tisagenlecleucel NICE information</a>
<b>Red</b>	Tivozanib		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Tivozanib NICE information</a>
<b>Red</b>	Tocilizumab		1,3	In line with positive NICE TAs. COVID-19 indication is for infusion only	Jun-23		<a href="#">Tocilizumab NICE Information</a>
<b>Red</b>	Tofacitinib		1	In line with positive NICE TA recommendations	Nov-23		<a href="#">Tofacitinib NICE information</a>
<b>Red</b>	Tolvaptan		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Tolvaptan NICE information</a>
<b>Red</b>	Topotecan		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Topotecan NICE information</a>
<b>Red</b>	Trabectedin		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Trabectedin NICE Information</a>
<b>Red</b>	Tralokinumab		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Tralokinumab NICE information</a>
<b>Red</b>	Trametinib		1	In line with positive NICE TA recommendations	Sep-23		<a href="#">Trametinib NICE information</a>
<b>Red</b>	Trastuzumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		<a href="#">Trastuzumab NICE information</a>
<b>Red</b>	Treosulfan		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Treosulfan NICE information</a>
<b>Red</b>	Treprostinil		1,6	All licensed indications	Nov-25		
<b>Red</b>	Tretinoin		1	All licensed indications	Nov-25		
<b>Red</b>	Trientine		1,6	All licensed indications	Nov-25		

Red	Trifluridine/Tipiracil		1,6	In line with positive NICE TAs	Feb-24	<a href="#">Trifluridine/Tipiracil NICE Information</a>
Red	Ublituximab		1,6	In line with positive NICE TA recommendations	Jan-25	<a href="#">Ublituximab NICE Information</a>
Red	Ulipristal acetate 5mg tablets	Esmya®	1	Fibroids	Feb-24	
Red	Upadacitinib		1,6	Crohn's disease	Jul-23	<a href="#">NICE TA905</a>
Red	Upadacitinib		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Upadacitinib NICE information</a>
Red	Ustekinumab		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Ustekinumab NICE information</a>
Red	Vadadustat		1,6	In line with positive NICE TA recommendations	Aug-24	<a href="#">Vadadustat NICE Information</a>
Red	Valganciclovir		1	All licensed indications	Nov-25	
Red	Vamorolone		1,6	In line with positive NICE TA recommendations	Feb-25	<a href="#">Vamorolone NICE Information</a>
Red	Vancomycin injection		1,5		Apr-26	
Red	Vanzacaftor-tezacaftor-deutivacaftor		1,6	treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over	Sep-25	<a href="#">NICE TA 1085</a>
Red	Varicella (chickenpox) vaccine	Varilrix®, Varivax®	6	Vaccine for use Prior to Immunosuppression, in Adults and Children without Immunity	Oct-23	
Red	Vasopressin		1	All licensed indications	Nov-25	
Red	Vedolizumab		1,6	In line with positive NICE TA recommendations	Feb-24	<a href="#">Vedolizumab NICE Information</a>
Red	Velmanase alfa		1,6	Alpha-mannosidosis	Feb-24	
Red	Venetoclax (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25	<a href="#">Venetoclax NICE information</a>
Red	Verteporfin		1	All licensed indications	Nov-25	
Red	Vinblastine		1	All licensed indications	Nov-25	
Red	Vincristine		1	All licensed indications	Dec-25	
Red	Vindesine		1	All licensed indications	Dec-25	

<b>Red</b>	Vinorelbine		1	All licensed indications	Dec-25		<a href="#">Volanesorsen NICE information</a>
<b>Red</b>	Vismodegib		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Vismodegib NICE information</a>
<b>Red</b>	Voclosporin		1,6	In line with positive NICE TA recommendations	Feb-24		<a href="#">Voclosporin NICE information</a>
<b>Red</b>	Volanesorsen		1,6	In line with NICE recommendations	Dec-25		
<b>Red</b>	Vonicog alfa			von willebrand disease	Dec-25		<a href="#">Voretigene neparvovec NICE information</a>
<b>Red</b>	Vorasidenib	Voranigo®	1,6	Treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 mutation or isocitrate dehydrogenase-2 mutation in adults and paediatric patients aged ≥12 years, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention	Dec-25		
<b>Red</b>	Voretigene neparvovec		1,6	In line with positive NICE TA recommendations	Dec-25		
<b>Red</b>	Voriconazole		1,6	All licensed indications	Dec-25		
<b>Red</b>	Vutrisiran		1,6	In line with positive NICE TA recommendations	Sep-23		<a href="#">Vutrisiran NICE information</a>
<b>Red</b>	Zanubrutinib ( including in combination with other drugs )		1,6	In line with positive NICE TA recommendations	Dec-23		<a href="#">Zanubrutinib NICE information</a>
<b>Red</b>	Zidovudine (in combination with other retroviral drugs)		1,6	HIV	Dec-25		
<b>Red</b>	Zolbetuximab (including in combination)		2	Advanced gastric or gastro-oesophageal junction adenocarcinoma	Apr-25		<a href="#">NICE TA 1046</a>

<b>Red</b>	Zoledronic acid		1	All licensed indications	Dec-25		
<b>Red</b>	Zuclopenthixol Acetate		1	Short term management of acute psychosis	May-25		
<b>Amber</b>	ACARIZAX 12 SQ-HDM		1,3	House dust mite sensitisation	May-22	Feb-27	<a href="#">Sublingual Immunotherapy (SCP)</a>
<b>Amber</b>	Acetazolamide		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Alimemazine (dual traffic light classification)	Izenal SF or Alfresed (sugary version)	1,2,3	Treatment of sleep disorders in Children ( from Specialist Clinicians at Sheffield Children's NHS Foundation Trust Tertiary Sleep Service only)	Aug-24	Aug-29	<a href="#">SY Alimemazine SCP</a>
<b>Amber</b>	Amantadine (Multiple traffic light classification)		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Apomorphine		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Azathioprine (dual Traffic Light status)		1,2 ab	In line with Place based shared care protocols, preparations within the documents. . Cross reference to Grey traffic light status for high strengths (75mg &100mg) Doncaster has a Red traffic light status - see Place based formulary for further information	Apr-24		
<b>Amber</b>	Brivaracetam		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>

<b>Amber</b>	Bromocriptine		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Cabergoline		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Carbamazepine		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Cenobamate (see appendix information for community pharmacy re ordering)		1,2,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Clobazam		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Clonazepam		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Co-beneldopa		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Co-careldopa		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Dalteparin		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP Refer to Place based guidance/ SCP for further information	Nov-24		<a href="#">Medicines Optimisation Information</a>
<b>Amber</b>	Dapsone (dual classification)		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		<a href="#">Medicines Optimisation Information</a>

<b>Amber</b>	Denosumab 60mg Injection	(Prolia®)	1,2,3	Indications as outlined in the Shared Care Protocol. Please note 120mg strength (XGEVA) is RED.	Aug-24	Aug-29	<a href="#">SY Denosumab SCP</a>
<b>Amber</b>	Diazepam (rectal)		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Entacapone		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Eslicarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Ethosuximide		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Finerenone		7	Chronic Kidney Disease in Type 2 Diabetes	Jun-24	Dec-25	<a href="#">SY Finerenone SCP</a>
<b>Amber</b>	Gabapentin		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	GRAZAX 75,000 SQ-T oral lyophilisate		1,3	Grass pollen sensitisation	May-22	Feb-27	<a href="#">Sublingual Immunotherapy (SCP)</a>
<b>Amber</b>	Hydrocortisone MR 5mg & 10mg capsules	Efmody®	1	Congenital adrenal hyperplasia	Sep-23		<a href="#">Link to SCP ( when uploaded on website)</a>
<b>Amber</b>	Lacosamide		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Lamotrigine		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Levetiracetam		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Liothyronine		1,2,3	From NHS Endocrinologists only	Aug-24	Aug-29	<a href="#">SY Liothyronine SCP</a>
<b>Amber</b>	Melatonin		1,3	For the treatment of sleep disorders in children and young people up to 18 years (off-label use)	Dec-25	Dec-28	<a href="#">Refer to Place based formularies</a> <a href="#">SY Childrens and young peoples Melatonin SCP</a>
<b>Amber</b>	Melatonin		1,3	As per Place shared care protocols	Oct-23		<a href="#">Melatonin Information</a>

<b>Amber</b>	Methylphenidate		1,2,3	Use as part of a comprehensive treatment programme for attention-deficit/ hyperactivity disorder in children aged ≥6 years and adults when remedial measures alone prove insufficient	Feb-24		<a href="#">Methylphenidate Information</a>
<b>Amber</b>	Midazolam (Buccal)		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Modafinil		1,3	Refer to Place based Shared care protocol/ prescribing guidance	Nov-20	Nov-25	<a href="#">Modafinil Information</a>
<b>Amber</b>	Mycophenolate (dual traffic light classification)		1,2,3	TLS Amber for shared care protocols and Red for all other indications Refer to SCP at Place	Aug-24		<a href="#">Mycophenolate Information</a>
<b>Amber</b>	Opicapone		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Oxcarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Perampanel		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Phenobarbital		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Phenytoin		1,3		Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Pramipexole		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Pregabalin		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Primidone		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>

<b>Amber</b>	Rasagiline		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Relugolix–estradiol–norethisterone acetate (Dual traffic light status)	Ryeqo®	3	Uterine Fibroids	Oct-24	Oct-27	<a href="#">SY Relugolix-estradiol-norethisterone acetate (Ryeqo®) Shared Care Protocol</a>
<b>Amber</b>	Riluzole		1,3	Riluzole Shared Care Protocol(see Place formulary )	Oct-23		<a href="#">Riluzole Medicines Optimisation Information</a>
<b>Amber</b>	Ropinirole		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Rotigotine		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Rufinamide		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Safinamide		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Selegiline		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Sodium Valproate		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Stalevo® (levodopa, carbidopa and entacapone)		1,3	Parkinson's medication	Nov-21	Nov-26	<a href="#">Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP</a>
<b>Amber</b>	Stiripentol		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Topiramate		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Vigabatrin		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>
<b>Amber</b>	Zonisamide		1,3	Epilepsy medication	Apr-22	Apr-27	<a href="#">SY &amp; Bassetlaw SCP for Epilepsy in Adults</a>

<b>Amber G</b>	Alpha Tocopheryl Acetate (Vitamin E)		1,2b	Following British National Formulary (BNF) advice	Mar-26		<a href="#">Alpha-Tocopheryl BNF Information</a>
<b>Amber G</b>	Alprostadil cream		1	Erectile dysfunction	Mar-26		
<b>Amber G</b>	Amantadine (multiple traffic light classification )			In Line with NICE guidance (Multiple-Sclerosis)	Feb-24		
<b>Amber G</b>	Atogepant		1,2b	Prevention of episodic and chronic migraine	Feb-26		<a href="#">Atogepant Amber G Guideline</a>
<b>Amber G</b>	Dexcom One +			Continuous Glucose Monitor	Nov-24		
<b>Amber G</b>	Duloxetine		1	Stress Urinary Incontinence	Sep-23		<a href="#">NICE NG123</a>
<b>Amber G</b>	Eflornithine cream		1,2	Treatment of facial hirsutism in women	Jul-23		<a href="#">NICE guidance</a>
<b>Amber G</b>	Empagliflozin (multiple classification)		1,2	For treating chronic heart failure with preserved or mildly reduced ejection fraction. Also cross- referenced to Green TLS for treatment of CKD	Dec-23		<a href="#">NICE TA929- Also has dual traffic light status</a>
<b>Amber G</b>	Fentanyl (Immediate release)		1,2b	For patients undergoing palliative care treatment as per NHSE guidance	Dec-23		<a href="#">NHS E Guideline</a>
<b>Amber G</b>	Freestyle Libre 2+			Continuous Glucose Monitor	Nov-24		<a href="#">SY CGM Guidance</a>
<b>Amber G</b>	Freestyle Libre Flash Glucose Monitoring System		1,2		Sep-23		<a href="#">SY CGM Guidance</a>
<b>Amber G</b>	Glucagon pre filled pen	Ogluo®	1, 2b	Severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.	May-23		
<b>Amber G</b>	Hydrocortisone oral solution		1,2a	Dual classification	Jun-24		
<b>Amber G</b>	Ibandronic acid		1,2b	Adjuvant therapy in early breast cancer	Feb-24		<a href="#">Ibandronic acid SY Guidance</a>

<b>Amber G</b>	latanoprost/netarsudil eye drops	Roclanda®		Previously treated primary open-angle glaucoma or ocular hypertension	Feb-26		<a href="#">NICE TA 1009</a>
<b>Amber G</b>	Metolazone 5mg	(Xaqua®)		Oedema related to kidney disease and Congestive Heart Failure (CHF)	Feb-24		<a href="#">Metolazone guideline</a>
<b>Amber G</b>	Progesterone 400mg soft vaginal capsules	Prometrium®	1,2b	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages	Feb-26		
<b>Amber G</b>	Progesterone micronised vaginal preparations (multiple traffic light classifications)		1,2b	Prevention of preterm birth.	May-26		<a href="#">Different products have different licensed indications - refer to the SPC.</a>
<b>Amber G</b>	Reboxetine		1,2a	Treatment of depression	Dec-23		
<b>Amber G</b>	Rimegepant (Dual classification)		1,2b	Prevention of episodic migraine Also cross reference to Green classification)	Feb-26		<a href="#">Rimegepant Amber G Guidance</a>
<b>Amber G</b>	Tirzepatide type 2 diabetes		1,2b	Treating type 2 diabetes.	Dec-23		<a href="#">SY Tirzepatide Amber G Guidance</a>
<b>Green</b>	Fluoride toothpastes (2800ppm and 5000ppm) ONLY (specialist recommendation)			High strength toothpaste (specialist recommendation) only when prescribing in line with the exceptions in the Position Statement.	May-25		<a href="#">SY Dental Statement</a>
<b>Green</b>	5 Fluorouracil and salicylic acid 5FU-SA	Actikerall		Treatment for Actinic Keratosis	Nov-25		<a href="#">SY Actinic Keratosis Guidance</a>
<b>Green</b>	Acetic acid 2%			Acute otitis externa	Mar-26		
<b>Green</b>	Aciclovir 3% eye ointment			Herpes Simplex infection	Aug-24		

<b>Green</b>	Adapalene plus benzoyl peroxide 0.1%/2.5%.			Acne	Mar-26	
<b>Green</b>	Adrenaline (Dual Traffic Light status)				Apr-24	
<b>Green</b>	Alginate antacid				Jun-24	
<b>Green</b>	Alverine with Simeticone			Irritable bowel syndrome	Jun-24	
<b>Green</b>	Aminophylline hydrate tablets			Indicated in adults and children aged 6 years and above for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. Indicated in adults for the treatment of left ventricular and congestive cardiac failure	Aug-24	
<b>Green</b>	Aspirin			All licensed indications & off-licensed use for hypertension in pregnancy	Nov-25	<a href="#">Aspirin in pregnancy NICE information</a>
<b>Green</b>	Betamethasone plasters			Corticosteroids (topical)	Aug-24	<a href="#">Betamethasone Plasters BNF information</a>
<b>Green</b>	Bilastine			Antihistamine	Mar-26	<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Bimatoprost + timolol				Mar-25	

<b>Green</b>	Bismuth subcitrate potassium , metronidazole , tetracycline hydrochloride 14mg/125mg/125mg	Pylera ®		Helicobacter Pylori eradication	May-26		<a href="#">Green for first line or second line use only to treat H.Pylori in those with penicillin allergy.</a>  <a href="#">See link for clinical scenarios where consideration may be indicated. Note the licensed treatment is for 10 days.</a>
<b>Green</b>	Brimonidine gel			Facial erythema of rosacea	Jun-24		
<b>Green</b>	Buprenorphine			Pain	Feb-26		
<b>Green</b>	Bupropion			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek cks for supporting information	Oct-24		
<b>Green</b>	Canagliflozin			Type 2 diabetes in adults	Nov-24		
<b>Green</b>	Cetirizine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Chlorphenamine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Cimetidine				Jun-24		
<b>Green</b>	Ciprofloxacin			Only as per NICE CKS antibiotics	Jun-24		
<b>Green</b>	Clindamycin/Tretinoin gel			Topical preparations for acne	Jun-24		

Green	Co-codamol 8/500mg for acute pain in adults			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24	
Green	Covid-19 vaccine			Covid -19 vaccine-as per NHS green book	May-23	
Green	Cyanocobalamin 50 microgram tablets (dual traffic light classification)	Cyanocominn®		As per NHSE guidance - only to be prescribed in those with medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Continuing need should however be reviewed on a regular basis. OTC advised if deficiency dietary related	May-23	
Green	Cytisinicline (cytisine)			To aid smoking cessation	May-26	<a href="#">Commissioned services must be used as the standard pathway. Primary care prescribing is only permitted in exceptional circumstances where these services are inaccessible. Please see CKS for supporting information (Cytisinicline   Prescribing information   Smoking cessation   CKS   NICE)</a>
Green	Dapagliflozin			Chronic heart failure with preserved or mildly reduced ejection fraction & Chronic kidney disease & Type 2 diabetes	Mar-26	<a href="#">SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure</a>

<b>Green</b>	Daridorexant			Insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, in line with the SYICB insomnia management pathway and NICE TA.	Mar-26		<a href="#">SY Daridorexant information</a>
<b>Green</b>	Dekas plus liquid (dual traffic light classification)			Children under 3 years with Cystic fibrosis Also see Grey Traffic Light Status	Oct-23		
<b>Green</b>	Desloratadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
<b>Green</b>	Desogestrel				Jun-24		
<b>Green</b>	Dexamethasone sodium phosphate eye drops				Jun-24		
<b>Green</b>	Diclofenac 3% gel	Solaraze®		Treatment for Actinic Keratosis	Nov-25		<a href="#">SY Actinic Keratosis Guidance</a>
<b>Green</b>	Diltiazem 2% cream/ ointment			anal fissure	Jun-24		
<b>Green</b>	Dorzolamide eye drops				Jun-24		
<b>Green</b>	Dorzolamide/timolol eye drops				Jun-24		
<b>Green</b>	Doxylamine & Pyridoxine	Xonvea®		Nausea and vomiting during pregnancy	Apr-24		
<b>Green</b>	Drospirenone	Slynd®		Refer to Place based formularies	Dec-23		
<b>Green</b>	Dutasteride				Jun-24		
<b>Green</b>	Dydrogesterone			For women with progesterone insufficiencies	Oct-25		

<b>Green</b>	Empagliflozin	Jardiance®		Chronic heart failure with preserved or mildly reduced ejection fraction & Chronic kidney disease & Type 2 diabetes	Mar-26		<a href="#">SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure</a>
<b>Green</b>	Enalapril				Jun-24		
<b>Green</b>	Ertugliflozin			Type 2 diabetes	Nov-24		
<b>Green</b>	Escitalopram			Treatment of major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder in adults	Aug-25		
<b>Green</b>	Esomeprazole				Jun-24		
<b>Green</b>	Estetrol + drospirenone				Jun-24		
<b>Green</b>	Estradiol and Progesterone				Jun-24		
<b>Green</b>	Estradiol plus Nomegestrol				Jun-24		
<b>Green</b>	Estradiol transdermal spray				Jun-24		
<b>Green</b>	Estradiol Valerate, dienogest	Qlaira		oral contraception	Aug-24		<a href="#">FSRH Clinical Guideline: Contraception for Women Aged over 40 Years</a>
<b>Green</b>	Estriol pessary				Jun-24		
<b>Green</b>	Estriol 1 mg/g vaginal cream				Oct-24		
<b>Green</b>	Estriol gel				Jun-24		
<b>Green</b>	Ethinylestradiol /drospirenone tablets				Jun-24		
<b>Green</b>	Fesoterodine fumarate				Jun-24		
<b>Green</b>	Fexofenadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		

<b>Green</b>	Fludrocortide			Refer to Place based formularies/guidelines for alternative listing	Jun-24		<a href="#">Medicines Optimisation Information</a>
<b>Green</b>	Fluorouracil cream			Treatment for Actinic Keratosis	Nov-25		<a href="#">SY Actinic Keratosis Guidance</a>
<b>Green</b>	Fluoxetine (with the exception of the 10mg tablet formulation - refer to the grey entry)			SSRI	Mar-26		
<b>Green</b>	Fluticasone Propionate including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24		<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Fluvastatin 20mg & 40mg				Jun-24		
<b>Green</b>	Folic Acid				Jun-24		
<b>Green</b>	Formoterol Fumarate including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24		<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Gestodene/ethinylestradiol				Jun-24		
<b>Green</b>	Glyceryl Trinitrate ointment			anal fissure	Jun-24		
<b>Green</b>	Glycopyrronium inhalation powder including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24		<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Hepatitis A vaccine			Immunisation-as per NHS green book	Sep-23		
<b>Green</b>	Hepatitis B vaccine			Immunisation-as per NHS green book	Sep-23		
<b>Green</b>	Hydrocortisone (topical)				Jun-24		
<b>Green</b>	Hydrocortisone eye drops				Jun-24		

<b>Green</b>	Hydroxocobalamin (dual traffic light)			Pernicious anaemia and other macrocytic anaemias (prophylaxis & treatment)	Sep-25	
<b>Green</b>	Hydroxyzine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26	<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Ibandronic acid 150mg			Osteoporosis	Jun-24	
<b>Green</b>	Ibuprofen			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24	
<b>Green</b>	Imiquimod cream			Treatment for Actinic Keratosis	Nov-25	<a href="#">SY Actinic Keratosis Guidance</a>
<b>Green</b>	Indacaterol including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24	<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Influenza vaccine			Active immunisation for the prevention of influenza disease	Nov-25	
<b>Green</b>	Insulin needles <£5 per 100 needles			Refer to Place based formulary/ guidelines/other resources for further details	Sep-23	<a href="#">Medicines Optimisation Information</a>
<b>Green</b>	Intravaginal device and pessaries			Non-surgical management of pelvic floor dysfunction	Feb-26	<a href="#">Prescribe on specialist recommendation and in line with NICE guidance</a>
<b>Green</b>	Ipratropium Bromide			Refer to Place based Asthma/ COPD guidelines	Jun-24	<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Isosorbide mononitrate				Jun-24	
<b>Green</b>	Ivermectin 3mg tablets (dual traffic light status)			Treatment of scabies Traffic Lighted as Red for all other indications	Nov-24	
<b>Green</b>	Latanoprost + timolol eye drops			Refer to Place Glaucoma guidelines	Oct-24	<a href="#">Place Glucoma Guidelines</a>
<b>Green</b>	Levocetirizine				Jun-24	
<b>Green</b>	Levofloxacin tablets			Antibiotic	Aug-24	<a href="#">Levofloxacin NICE information</a>

<b>Green</b>	Levomepromazine			The 6.25mg tablet is more cost effective than the 6mg tablet.	Mar-24	
<b>Green</b>	Levonorgestrel				Jun-24	
<b>Green</b>	Levonorgestrel intrauterine delivery system				Jun-24	
<b>Green</b>	Lodoxamide eye drops				Jun-24	
<b>Green</b>	Loratadine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26	<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Macrogol 3350 sachet				Jun-24	
<b>Green</b>	Mebeverine				Jun-24	
<b>Green</b>	Meloxicam			NSAID	Oct-25	<a href="#">Refer to Place based formularies</a>
<b>Green</b>	Methenamine hippurate 1g tablets			Urinary tract infection	Apr-23	<a href="#">NICE NG112</a>
<b>Green</b>	Mirabegron			In line with positive NICE TA recommendations		<a href="#">Mirabegron NICE Information</a>
<b>Green</b>	Misoprostol (multiple traffic light classifications)			GI and musculoskeletal	Oct-25	
<b>Green</b>	Mometasone including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24	<a href="#">Asthma and COPD Information</a>
<b>Green</b>	Morphine sulphate			Cross reference Traffic Light Status Red	Jun-24	
<b>Green</b>	Nabumetone				Jun-24	

<b>Green</b>	Nicotine replacement products eg Patches,gum,lozenges,inhalators, sprays and sublingual tablets			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24	
<b>Green</b>	Nifedipine				Jun-24	
<b>Green</b>	Ofloxacin			Only as per NICE CKS antibiotics	Jun-24	
<b>Green</b>	Olopatadine hydrochloride, Mometasone furoate monohydrate	Ryaltris		Indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis	May-24	
<b>Green</b>	Ondansetron				Jan-26	
<b>Green</b>	Oral Combined hormone contraception				Aug-24	
<b>Green</b>	Ospemifene tablets			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26	<a href="#">When prescribed in line with NICE NG23 1.5.11</a>
<b>Green</b>	Phenazone 40mg/1g, Lidocaine 10mg/1g ear drops	Otigo®		Local symptomatic treatment and relief of pain in the middle ear	Apr-23	<a href="#">NICE NG91</a>
<b>Green</b>	Pneumococcal polysaccharide conjugate vaccine			Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older	Apr-26	<a href="#">Pneumococcal: the Green Book, Chapter 25</a>

<b>Green</b>	Prasterone pessaries			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26		<a href="#">When prescribed in line with NICE NG23 1.5.10</a>
<b>Green</b>	Pregabalin			Neuropathic pain	Apr-25		
<b>Green</b>	Primidone			Essential tremor	Feb-26		
<b>Green</b>	Promethazine			Antihistamine	Mar-26		<a href="#">Follow Place formularies / guidelines for further information</a>
<b>Green</b>	Rehydration solutions/sachets (dual traffic light status)			For all other conditions than acute diarrhoea	Feb-24		
<b>Green</b>	Respiratory syncytial virus vaccine				Dec-23		<a href="#">RSV Green Book Chapter updated February 2025</a>
<b>Green</b>	Rimegepant (Dual classification)			Treatment of acute migraine (cross reference to Amber G classification)	Jul-24		<a href="#">Neurology:migraine management guidelines</a>
<b>Green</b>	Salmeterol including combination products			SY Asthma/ COPD guidelines	Jun-24		<a href="#">Asthma &amp; COPD guidelines and Information</a>
<b>Green</b>	Sildenafil (generic) (For Erectile Dysfunction) 25mg,50mg,100mg (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		<a href="#">Erectile Dysfunction Information</a>
<b>Green</b>	Sildenafil citrate			Erectile dysfunction	Sep-25		
<b>Green</b>	Spironolactone				Feb-25		
<b>Green</b>	Tadalafil 5mg ( daily )			Refer to place based formularies for further details	Jul-25		<a href="#">Medicines Optimisation Information</a>

<b>Green</b>	Tadalafil 10mg & 20mg (generic) (For Erectile Dysfunction) (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		<a href="#">Erectile Dysfunction Information</a>
<b>Green</b>	Tirbaniulin ointment	Klisyri®		Treatment for Actinic Keratosis	Nov-25		<a href="#">SY Actinic Keratosis Guidance</a>
<b>Green</b>	Tirzepatide (cohort ONE weight management patients only ) [Multiple traffic light classifications]			Traffic Lighted as Green for cohort ONE weight management patients only (refer to local clinical guidance for further information).	Nov-25		<a href="#">Tirzepatide weight management Information</a>
<b>Green</b>	Tozinameran + famtozinameran	Comirnaty® Original/Omicron BA.4/5		Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥12 years who have previously received at least a primary vaccination course against COVID-19	Jun-23		
<b>Green</b>	Vardenafil			Erectile Dysfunction. Follow Place formularies / guidelines for further information	Nov-25		<a href="#">Erectile Dysfunction Information</a>
<b>Green</b>	Varenicline			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24		<a href="#">Medicines Optimisation Information</a>
<b>Green</b>	Vibegron			Treating symptoms of overactive bladder syndrome	Oct-24		<a href="#">NICE TA999</a>

<b>Green</b>	Zolpidem			Short-term treatment of insomnia in adults in situations where the insomnia is debilitating or is causing severe distress for the patient	Sep-25		
--------------	----------	--	--	---	--------	--	--